Cover Page
Cover Page - shares | 6 Months Ended | |
Jun. 30, 2019 | Jul. 31, 2019 | |
Cover page. | ||
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Jun. 30, 2019 | |
Document Transition Report | false | |
Entity File Number | 001-36042 | |
Entity Registrant Name | INTREXON CORPORATION | |
Entity Incorporation, State or Country Code | VA | |
Entity Tax Identification Number | 26-0084895 | |
Entity Address, Address Line One | 20374 Seneca Meadows Parkway | |
Entity Address, City or Town | Germantown, | |
Entity Address, State or Province | MD | |
Entity Address, Postal Zip Code | 20876 | |
City Area Code | 301 | |
Local Phone Number | 556-9900 | |
Title of 12(b) Security | Common Stock, no par value | |
Trading Symbol | XON | |
Security Exchange Name | NASDAQ | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Large Accelerated Filer | |
Entity Small Business | false | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 162,070,609 | |
Amendment Flag | false | |
Document Fiscal Year Focus | 2019 | |
Document Fiscal Period Focus | Q2 | |
Entity Central Index Key | 0001356090 | |
Current Fiscal Year End Date | --12-31 |
Consolidated Balance Sheets
Consolidated Balance Sheets - USD ($) $ in Thousands | Jun. 30, 2019 | Dec. 31, 2018 |
Current assets | ||
Cash and cash equivalents | $ 58,162 | $ 102,768 |
Restricted cash | 0 | 6,987 |
Short-term investments | 67,641 | 119,688 |
Equity securities | 0 | 384 |
Receivables | ||
Trade, net | 24,496 | 21,195 |
Related parties, net | 7,095 | 4,129 |
Other, net | 2,866 | 2,754 |
Inventory | 18,192 | 21,447 |
Prepaid expenses and other | 4,712 | 6,131 |
Total current assets | 183,164 | 285,483 |
Equity securities, noncurrent | 21,503 | 1,798 |
Property, plant and equipment, net | 120,401 | 128,874 |
Intangible assets, net | 112,526 | 129,291 |
Goodwill | 149,916 | 149,585 |
Investments in affiliates | 18,093 | 18,859 |
Right-of-use assets | 41,558 | 0 |
Other assets | 8,027 | 2,287 |
Total assets | 655,188 | 716,177 |
Current liabilities | ||
Accounts payable | 8,563 | 13,420 |
Accrued compensation and benefits | 9,034 | 10,687 |
Other accrued liabilities | 11,701 | 20,620 |
Deferred revenue, including $7,053 and $6,945 from related parties as of June 30, 2019 and December 31, 2018, respectively | 16,593 | 15,554 |
Lines of credit | 387 | 466 |
Current portion of long-term debt | 468 | 559 |
Current portion of lease liabilities | 4,813 | 0 |
Related party payables | 74 | 256 |
Total current liabilities | 51,633 | 61,562 |
Long-term debt, net of current portion, including $55,743 and $55,290 to related parties as of June 30, 2019 and December 31, 2018, respectively | 212,479 | 211,235 |
Deferred revenue, net of current portion, including $51,195 and $52,227 from related parties as of June 30, 2019 and December 31, 2018, respectively | 66,542 | 54,210 |
Lease liabilities, net of current portion | 38,757 | 0 |
Deferred tax liabilities, net | 6,332 | 7,213 |
Other long-term liabilities | 222 | 3,235 |
Total liabilities | 375,965 | 337,455 |
Commitments and contingencies (Note 16) | ||
Total equity | ||
Common stock, no par value, 400,000,000 and 200,000,000 shares authorized as of June 30, 2019 and December 31, 2018, respectively; 161,917,424 and 160,020,466 shares issued and outstanding as of June 30, 2019 and December 31, 2018, respectively | 0 | 0 |
Additional paid-in capital | 1,737,449 | 1,722,012 |
Accumulated deficit | (1,430,020) | (1,330,545) |
Accumulated other comprehensive loss | (28,206) | (28,612) |
Total Intrexon shareholders' equity | 279,223 | 362,855 |
Noncontrolling interests | 0 | 15,867 |
Total equity | 279,223 | 378,722 |
Total liabilities and total equity | $ 655,188 | $ 716,177 |
Consolidated Balance Sheets (Pa
Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands | Jun. 30, 2019 | Dec. 31, 2018 |
Related Party Transaction [Line Items] | ||
Current portion of deferred revenue | $ 16,593 | $ 15,554 |
Long-term portion of deferred revenue | 66,542 | 54,210 |
Long-term debt, less current portion | $ 212,479 | $ 211,235 |
Common stock, shares authorized (in shares) | 400,000,000 | 200,000,000 |
Common stock, shares issued (in shares) | 161,917,424 | 160,020,466 |
Common stock, shares outstanding (in shares) | 161,917,424 | 160,020,466 |
Related Parties, Aggregated | ||
Related Party Transaction [Line Items] | ||
Current portion of deferred revenue | $ 7,053 | $ 6,945 |
Long-term portion of deferred revenue | 51,195 | 52,227 |
Long-term debt, less current portion | $ 55,743 | $ 55,290 |
Consolidated Statements of Oper
Consolidated Statements of Operations - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2019 | Jun. 30, 2018 | Jun. 30, 2019 | Jun. 30, 2018 | |
Revenues | ||||
Revenues | $ 35,986 | $ 45,275 | $ 59,321 | $ 84,941 |
Operating Expenses | ||||
Research and development | 34,518 | 42,049 | 67,580 | 79,187 |
Selling, general and administrative | 21,483 | 34,427 | 55,077 | 74,164 |
Total operating expenses | 73,395 | 95,010 | 155,433 | 187,198 |
Operating loss | (37,409) | (49,735) | (96,112) | (102,257) |
Other Expense, Net | ||||
Unrealized and realized appreciation (depreciation) in fair value of equity securities and preferred stock, net | 5,632 | (19,182) | 5,702 | (20,278) |
Interest expense | (4,358) | (142) | (8,669) | (241) |
Interest and dividend income | 1,031 | 5,746 | 2,395 | 11,216 |
Other expense, net | (2,605) | (93) | (2,099) | (881) |
Total other expense, net | (300) | (13,671) | (2,671) | (10,184) |
Equity in net loss of affiliates | (1,747) | (4,550) | (3,387) | (7,010) |
Loss before income taxes | (39,456) | (67,956) | (102,170) | (119,451) |
Income tax benefit | 525 | 1,127 | 1,103 | 5,213 |
Net loss | (38,931) | (66,829) | (101,067) | (114,238) |
Net loss attributable to the noncontrolling interests | 165 | 1,447 | 1,592 | 2,691 |
Net loss attributable to Intrexon | $ (38,766) | $ (65,382) | $ (99,475) | $ (111,547) |
Net loss attributable to Intrexon per share, basic and diluted (in usd per share) | $ (0.25) | $ (0.51) | $ (0.65) | $ (0.87) |
Weighted average shares outstanding, basic and diluted (in shares) | 153,749,929 | 129,299,584 | 153,351,208 | 128,500,897 |
Collaboration and licensing agreements | ||||
Revenues | ||||
Revenues | $ 9,097 | $ 17,450 | $ 15,067 | $ 37,298 |
Products | ||||
Revenues | ||||
Revenues | 7,819 | 9,568 | 12,676 | 16,720 |
Operating Expenses | ||||
Cost of products and services | 9,176 | 10,639 | 17,466 | 19,169 |
Services | ||||
Revenues | ||||
Revenues | 18,400 | 17,718 | 29,783 | 29,965 |
Operating Expenses | ||||
Cost of products and services | 8,218 | 7,895 | 15,310 | 14,678 |
Other | ||||
Revenues | ||||
Revenues | $ 670 | $ 539 | $ 1,795 | $ 958 |
Consolidated Statements of Op_2
Consolidated Statements of Operations (Parenthetical) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2019 | Jun. 30, 2018 | Jun. 30, 2019 | Jun. 30, 2018 | |
Related Party Transaction [Line Items] | ||||
Revenues | $ 35,986 | $ 45,275 | $ 59,321 | $ 84,941 |
Collaboration and licensing agreements | ||||
Related Party Transaction [Line Items] | ||||
Revenues | 9,097 | 17,450 | 15,067 | 37,298 |
Collaboration and licensing agreements | Related Parties, Aggregated | ||||
Related Party Transaction [Line Items] | ||||
Revenues | $ 7,110 | $ 13,148 | $ 10,922 | $ 29,788 |
Consolidated Statements of Comp
Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2019 | Jun. 30, 2018 | Jun. 30, 2019 | Jun. 30, 2018 | |
Statement of Comprehensive Income [Abstract] | ||||
Net loss | $ (38,931) | $ (66,829) | $ (101,067) | $ (114,238) |
Other comprehensive income (loss): | ||||
Unrealized gain on investments | 59 | 0 | 106 | 2 |
Gain (loss) on foreign currency translation adjustments | 26 | (12,153) | 311 | (6,293) |
Comprehensive loss | (38,846) | (78,982) | (100,650) | (120,529) |
Comprehensive loss attributable to the noncontrolling interests | 199 | 1,489 | 1,581 | 2,792 |
Comprehensive loss attributable to Intrexon | $ (38,647) | $ (77,493) | $ (99,069) | $ (117,737) |
Consolidated Statements of Shar
Consolidated Statements of Shareholders' and Total Equity - USD ($) $ in Thousands | Total | Common Stock | Additional Paid-in Capital | Accumulated Other Comprehensive Loss | Accumulated Deficit | Total Intrexon Shareholders' Equity | Noncontrolling Interests |
Balances (in shares) at Dec. 31, 2017 | 122,087,040 | ||||||
Balances at Dec. 31, 2017 | $ 546,545 | $ 0 | $ 1,397,005 | $ (15,554) | $ (847,820) | $ 533,631 | $ 12,914 |
Increase (Decrease) in Stockholders' Equity | |||||||
Cumulative effect of adoption of new accounting pronouncements | 26,507 | (104) | 26,611 | 26,507 | |||
Stock-based compensation expense | 20,208 | 20,154 | 20,154 | 54 | |||
Shares issued upon vesting of restricted stock units and for exercises of stock options and warrants (in shares) | 27,033 | ||||||
Shares issued upon vesting of restricted stock units and for exercises of stock options and warrants | 933 | 121 | 121 | 812 | |||
Shares issued as payment for services (in shares) | 407,715 | ||||||
Shares issued as payment for services | 5,487 | 5,487 | 5,487 | 0 | |||
Shares and warrants issued in public offerings, net of issuance costs (in shares) | 6,900,000 | ||||||
Shares and warrants issued in public offerings, net of issuance costs | 87,990 | 82,374 | 82,374 | 5,616 | |||
Adjustments for noncontrolling interests | 0 | (785) | (785) | 785 | |||
Net loss | (114,238) | (111,547) | (111,547) | (2,691) | |||
Other comprehensive income (loss) | (6,291) | (6,190) | (6,190) | (101) | |||
Balances (in shares) at Jun. 30, 2018 | 129,421,788 | ||||||
Balances at Jun. 30, 2018 | 567,141 | $ 0 | 1,504,356 | (21,848) | (932,756) | 549,752 | 17,389 |
Balances (in shares) at Mar. 31, 2018 | 129,239,376 | ||||||
Balances at Mar. 31, 2018 | 634,122 | $ 0 | 1,492,916 | (9,737) | (867,374) | 615,805 | 18,317 |
Increase (Decrease) in Stockholders' Equity | |||||||
Stock-based compensation expense | 8,846 | 8,814 | 8,814 | 32 | |||
Shares issued upon vesting of restricted stock units and for exercises of stock options and warrants (in shares) | 5,311 | ||||||
Shares issued upon vesting of restricted stock units and for exercises of stock options and warrants | 609 | 47 | 47 | 562 | |||
Shares issued as payment for services (in shares) | 177,101 | ||||||
Shares issued as payment for services | 2,546 | 2,546 | 2,546 | ||||
Adjustments for noncontrolling interests | 0 | 33 | 33 | (33) | |||
Net loss | (66,829) | (65,382) | (65,382) | (1,447) | |||
Other comprehensive income (loss) | (12,153) | (12,111) | (12,111) | (42) | |||
Balances (in shares) at Jun. 30, 2018 | 129,421,788 | ||||||
Balances at Jun. 30, 2018 | $ 567,141 | $ 0 | 1,504,356 | (21,848) | (932,756) | 549,752 | 17,389 |
Balances (in shares) at Dec. 31, 2018 | 160,020,466 | 160,020,466 | |||||
Balances at Dec. 31, 2018 | $ 378,722 | $ 0 | 1,722,012 | (28,612) | (1,330,545) | 362,855 | 15,867 |
Increase (Decrease) in Stockholders' Equity | |||||||
Stock-based compensation expense | 9,115 | 9,046 | 9,046 | 69 | |||
Shares issued upon vesting of restricted stock units and for exercises of stock options and warrants (in shares) | 632,015 | ||||||
Shares issued upon vesting of restricted stock units and for exercises of stock options and warrants | 307 | 57 | 57 | 250 | |||
Shares issued for accrued compensation (in shares) | 150,908 | ||||||
Shares issued for accrued compensation | 1,102 | 1,102 | 1,102 | ||||
Shares issued as payment for services (in shares) | 1,114,035 | ||||||
Shares issued as payment for services | 5,688 | 5,688 | 5,688 | ||||
Shares and warrants issued in public offerings, net of issuance costs | 6,611 | 6,611 | |||||
Adjustments for noncontrolling interests | 0 | (456) | (456) | 456 | |||
Deconsolidation of subsidiary | (21,672) | (21,672) | |||||
Net loss | (101,067) | (99,475) | (99,475) | (1,592) | |||
Other comprehensive income (loss) | $ 417 | 406 | 406 | 11 | |||
Balances (in shares) at Jun. 30, 2019 | 161,917,424 | 161,917,424 | |||||
Balances at Jun. 30, 2019 | $ 279,223 | $ 0 | 1,737,449 | (28,206) | (1,430,020) | 279,223 | 0 |
Balances (in shares) at Mar. 31, 2019 | 160,615,416 | ||||||
Balances at Mar. 31, 2019 | 334,823 | $ 0 | 1,732,608 | (28,325) | (1,391,254) | 313,029 | 21,794 |
Increase (Decrease) in Stockholders' Equity | |||||||
Stock-based compensation expense | 61 | 56 | 56 | 5 | |||
Shares issued upon vesting of restricted stock units and for exercises of stock options and warrants (in shares) | 345,378 | ||||||
Shares issued upon vesting of restricted stock units and for exercises of stock options and warrants | 0 | 0 | 0 | 0 | |||
Shares issued as payment for services (in shares) | 956,630 | ||||||
Shares issued as payment for services | 4,857 | 4,857 | 4,857 | ||||
Adjustments for noncontrolling interests | 0 | (72) | (72) | 72 | |||
Deconsolidation of subsidiary | (21,672) | (21,672) | |||||
Net loss | (38,931) | (38,766) | (38,766) | (165) | |||
Other comprehensive income (loss) | $ 85 | 119 | 119 | (34) | |||
Balances (in shares) at Jun. 30, 2019 | 161,917,424 | 161,917,424 | |||||
Balances at Jun. 30, 2019 | $ 279,223 | $ 0 | $ 1,737,449 | $ (28,206) | $ (1,430,020) | $ 279,223 | $ 0 |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows - USD ($) $ in Thousands | 6 Months Ended | |
Jun. 30, 2019 | Jun. 30, 2018 | |
Cash flows from operating activities | ||
Net loss | $ (101,067) | $ (114,238) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Depreciation and amortization | 12,690 | 16,881 |
Loss on disposal of assets, net | 1,286 | 5,585 |
Unrealized and realized (appreciation) depreciation on equity securities and preferred stock, net | (5,702) | 20,278 |
Noncash dividend income | (25) | (9,914) |
Amortization of premiums (discounts) on investments, net | (693) | 0 |
Equity in net loss of affiliates | 3,387 | 7,010 |
Stock-based compensation expense | 9,115 | 20,208 |
Shares issued as payment for services | 5,688 | 5,487 |
Provision for bad debts | 344 | 789 |
Accretion of debt discount and amortization of deferred financing costs | 4,532 | 0 |
Deferred income taxes | (981) | (5,089) |
Other noncash items | 3,166 | 205 |
Receivables: | ||
Trade | (3,743) | (3,639) |
Related parties | (3,317) | 6,279 |
Other | 296 | (53) |
Inventory | 3,096 | 432 |
Prepaid expenses and other | 45 | 1,284 |
Right-of-use assets | 2,639 | 0 |
Other assets | (1,202) | 102 |
Accounts payable | (3,686) | (468) |
Accrued compensation and benefits | (347) | 7,597 |
Other accrued liabilities | (7,855) | (1,165) |
Deferred revenue | 8,890 | (15,648) |
Lease liabilities | (2,675) | 0 |
Related party payables | 67 | (199) |
Other long-term liabilities | (585) | 218 |
Net cash used in operating activities | (76,637) | (58,058) |
Cash flows from investing activities | ||
Purchases of investments | (37,163) | (76) |
Maturities of investments | 90,000 | 6,000 |
Proceeds from sales of equity securities | 589 | 217 |
Investments in affiliates | (2,370) | (8,510) |
Decrease in cash from deconsolidation of subsidiary | (7,244) | 0 |
Return of investment in affiliate | 0 | 2,598 |
Purchases of property, plant and equipment | (25,423) | (21,589) |
Proceeds from sale of assets | 176 | 440 |
Net cash provided by (used in) investing activities | 18,565 | (20,920) |
Cash flows from financing activities | ||
Proceeds from issuance of shares and warrants in public offerings, net of issuance costs | 6,611 | 87,990 |
Advances from lines of credit | 3,250 | 2,278 |
Repayments of advances from lines of credit | (3,329) | (1,937) |
Proceeds from long-term debt, net of issuance costs | 376 | 0 |
Payments of long-term debt | (321) | (281) |
Proceeds from stock option and warrant exercises | 307 | 933 |
Payment of issuance costs | 0 | (37) |
Net cash provided by financing activities | 6,894 | 88,946 |
Effect of exchange rate changes on cash, cash equivalents, and restricted cash | (418) | 381 |
Net increase (decrease) in cash, cash equivalents, and restricted cash | (51,596) | 10,349 |
Cash, cash equivalents, and restricted cash | ||
Beginning of period | 110,182 | 75,545 |
End of period | 58,586 | 85,894 |
Supplemental disclosure of cash flow information | ||
Cash paid during the period for interest | 3,637 | 195 |
Cash paid during the period for income taxes | 40 | 163 |
Significant noncash financing and investing activities | ||
Purchases of property and equipment included in accounts payable and other accrued liabilities | 1,010 | 2,051 |
Purchases of equipment financed through debt | 0 | 76 |
Issuance costs included in accounts payable and other accrued liabilities | $ 0 | $ 320 |
Consolidated Statements of Ca_2
Consolidated Statements of Cash Flows (Parenthetical) - USD ($) $ in Thousands | Jun. 30, 2019 | Dec. 31, 2018 |
Statement of Cash Flows [Abstract] | ||
Cash and cash equivalents | $ 58,162 | $ 102,768 |
Restricted cash | 0 | 6,987 |
Restricted cash included in other assets | 424 | 427 |
Cash, cash equivalents, and restricted cash | $ 58,586 | $ 110,182 |
Organization
Organization | 6 Months Ended |
Jun. 30, 2019 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Organization | Organization Intrexon Corporation ("Intrexon"), a Virginia corporation, uses synthetic biology to focus on programming biological systems to alleviate disease, remediate environmental challenges, and provide sustainable food and industrial chemicals, which may be accomplished directly or through collaborations and joint ventures. Intrexon's primary domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Hungary. There have been no commercialized products derived either directly by Intrexon or through its collaborations or joint ventures to date. Precigen, Inc. ("Precigen"), a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cellular therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases, is a wholly owned subsidiary of Intrexon with primary operations in Maryland. ActoBio Therapeutics, Inc. ("ActoBio") is pioneering a new class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics and is a wholly owned subsidiary of Intrexon with primary operations in Belgium. Trans Ova Genetics, L.C. ("Trans Ova"), Progentus, L.C. ("Progentus"), and ViaGen, L.C. ("ViaGen"), providers of advanced reproductive technologies, including services and products sold to cattle breeders and other producers, are wholly owned subsidiaries with primary operations in California, Iowa, Maryland, Missouri, New York, Oklahoma, Texas, and Washington. Oxitec Limited ("Oxitec"), a pioneering company in biological insect control solutions, is a wholly owned subsidiary of Intrexon with primary operations in Brazil and the United Kingdom. Intrexon Produce Holdings, Inc. ("IPHI") is a wholly owned subsidiary of Intrexon. Okanagan Specialty Fruits, Inc. ("Okanagan Specialty Fruits"), a company that developed and received regulatory approval for the world's first non-browning apple without the use of any artificial additives, is a wholly owned subsidiary of IPHI with primary operations in Canada. Fruit Orchard Holdings, Inc. ("FOHI") is a wholly owned subsidiary of IPHI with primary operations in Washington. IPHI and its subsidiaries are hereinafter referred to as "Okanagan." Exemplar Genetics, LLC ("Exemplar"), a provider of genetically engineered swine for medical and genetic research, is a wholly owned subsidiary with primary operations in Iowa. Through April 8, 2019, Intrexon consolidated AquaBounty Technologies, Inc. ("AquaBounty"), a company focused on improving productivity in commercial aquaculture and whose common stock is listed on the Nasdaq Stock Market. On April 9, 2019, AquaBounty completed an underwritten public offering that resulted in Intrexon no longer having the contractual right to control AquaBounty's board of directors, and accordingly, Intrexon deconsolidated AquaBounty. After remeasuring its retained interest in AquaBounty, Intrexon recorded a loss on deconsolidation of $2,648 , which is included in other expense, net, on the accompanying consolidated statements of operations for the three and six months ended June 30, 2019 . The deconsolidation resulted in the derecognition of the carrying amount of $38,682 in net assets that are no longer reported in the accompanying consolidated balance sheet as of June 30, 2019 . See Notes 9 , 10 , and 11 for additional discussion of material impacts to the accompanying consolidated balance sheet as of June 30, 2019 . As of June 30, 2019 , Intrexon owned approximately 38% of AquaBounty and, after deconsolidating the entity, accounts for these equity securities using the fair value option (Note 2 ). See Note 2 for additional discussion of Intrexon's investment in AquaBounty. Intrexon Corporation and its consolidated subsidiaries are hereinafter referred to as the "Company." |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 6 Months Ended |
Jun. 30, 2019 | |
Accounting Policies [Abstract] | |
Summary of Significant Accounting Policies | Summary of Significant Accounting Policies Basis of Presentation The accompanying interim consolidated financial statements are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"). Certain information and footnote disclosures normally included in the Company's annual financial statements have been condensed or omitted. These interim consolidated financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for fair statement of the Company's financial position as of June 30, 2019 and results of operations and cash flows for the interim periods ended June 30, 2019 and 2018 . The year-end consolidated balance sheet data was derived from the Company's audited financial statements but does not include all disclosures required by U.S. GAAP. These interim financial results are not necessarily indicative of the results to be expected for the year ending December 31, 2019 , or for any other future annual or interim period. The accompanying interim unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2018 . The accompanying consolidated financial statements reflect the operations of the Company and its subsidiaries. All intercompany accounts and transactions have been eliminated. Liquidity and Going Concern The Company has incurred operating losses since its inception and management expects operating losses and negative cash flows to continue for the foreseeable future and, as a result, the Company will require additional capital to fund its operations and execute its business plan. As of June 30, 2019 , the Company had $125,803 in cash, cash equivalents and short-term investments which is not sufficient to fund the Company's planned operations through one year after the date the interim unaudited consolidated financial statements are issued, and accordingly, there is substantial doubt about the Company's ability to continue as a going concern. The analysis used to determine the Company's ability to continue as a going concern does not include cash sources outside of the Company's direct control that management expects to be available within the next twelve months. The Company may not be able to obtain sufficient additional funding through monetizing certain of its existing assets, entering into new license and collaboration agreements, issuing additional equity or debt instruments or any other means, and if it is able to do so, they may not be on satisfactory terms. The Company's ability to raise additional capital in the equity and debt markets, should the Company choose to do so, is dependent on a number of factors, including, but not limited to, the market demand for the Company's common stock, which itself is subject to a number of business risks and uncertainties, as well as the uncertainty that the Company would be able to raise such additional capital at a price or on terms that are favorable to the Company. Should the Company not be able to secure additional funding through these means, the Company may have to engage in any or all of the following activities: (i) shift the Company's internal investments from subsidiaries and platforms whose potential for value creation is longer-term to near-term opportunities; (ii) sell certain of our operating subsidiaries to third parties; (iii) reduce operating expenditures for third-party contractors, including consultants, professional advisors, and other vendors; and (iv) reduce or delay capital expenditures, including non-essential facility expansions, lab equipment, and information technology projects. These actions may have a material adverse impact on the Company's ability to achieve certain of its planned objectives. Even if the Company is able to source additional funding, it may be forced to significantly reduce its operations if its business prospects do not improve. If the Company is unable to source additional funding, it may be forced to shut down operations altogether. These interim unaudited consolidated financial statements have been prepared on a going concern basis and do not include any adjustments to the amounts and classification of assets and liabilities that may be necessary in the event the Company can no longer continue as a going concern. Equity Securities The Company holds equity securities of private and publicly traded companies, including investments received and/or purchased from certain collaborators. The Company elected the fair value option to account for its equity securities held in publicly traded companies. These equity securities are recorded at fair value at each reporting date and are subject to market price volatility. Unrealized gains and losses resulting from fair value adjustments are reported in the consolidated statements of operations. The fair value of these equity securities is subject to fluctuation in the future due to the volatility of the stock market, changes in general economic conditions and changes in the financial conditions of these collaborators. The Company accounts for its investments in private companies using either the equity method, as discussed below, or the measurement alternative method for equity securities without readily determinable fair values, which represents cost and any adjustments for impairment or observable price changes in certain transactions. Equity securities that the Company does not intend to sell within one year are classified as noncurrent in the consolidated balance sheet. For equity securities received pursuant to a collaboration agreement, the Company records the fair value of securities received on the date the collaboration is consummated or the milestone is achieved using the fair value of the collaborator's security on that date, assuming the transfer of consideration is considered perfunctory. If the transfer of the consideration is not considered perfunctory, the Company considers the specific facts and circumstances to determine the appropriate date on which to evaluate fair value. The Company also evaluates whether any discounts for trading restrictions or other basis for lack of marketability should be applied to the fair value of the securities at inception of the collaboration. In the event the Company concludes that a discount should be applied, the fair value of the securities is adjusted at inception of the collaboration and re-evaluated at each reporting period thereafter. Equity Method Investments The Company accounts for its investments in each of its joint ventures and for its investments in start-up entities backed by the Harvest Intrexon Enterprise Fund I, LP ("Harvest"), all of which are related parties, using the equity method of accounting based upon relative ownership interest. The Company's investments in these entities are included in investments in affiliates in the accompanying consolidated balance sheets. See additional discussion related to certain of the Harvest start-up entities in Note 3 . Effective in April 2019, the Company accounts for its investment in AquaBounty, a related party, using the fair value option. The fair value of the Company's investment in AquaBounty was $20,041 as of June 30, 2019 and is included in equity securities, noncurrent, in the accompanying consolidated balance sheet. The Company's ownership of AquaBounty was approximately 38% as of June 30, 2019 . Unrealized appreciation in the fair value of the Company's investment in AquaBounty common stock was $5,802 for the three and six months ended June 30, 2019 . See Note 1 for additional discussion regarding AquaBounty. The Company accounts for its investment in Oragenics, Inc. ("Oragenics"), one of its collaborators and a related party, using the fair value option. Oragenics was considered an equity method investment through September 30, 2018. See Note 17 for additional discussion regarding Oragenics. Unrealized depreciation in the fair value of the Company's investment in Oragenics common stock was $409 and $1,160 for the three and six months ended June 30, 2018 , respectively. Summarized financial data as of June 30, 2019 and December 31, 2018 and for the three and six months ended June 30, 2019 and 2018 , for the Company's equity method investments are shown in the following tables. June 30, December 31, Current assets $ 22,159 $ 17,485 Noncurrent assets 58,286 31,274 Total assets 80,445 48,759 Current liabilities 7,260 4,226 Noncurrent liabilities 4,872 — Total liabilities 12,132 4,226 Net assets $ 68,313 $ 44,533 Three Months Ended Six Months Ended 2019 2018 2019 2018 Revenues $ 297 $ 173 $ 395 $ 240 Operating expenses 9,384 10,531 14,761 19,141 Operating loss (9,087 ) (10,358 ) (14,366 ) (18,901 ) Other, net 4 7 8 21 Net loss $ (9,083 ) $ (10,351 ) $ (14,358 ) $ (18,880 ) Variable Interest Entities As of June 30, 2019 and December 31, 2018 , the Company determined that certain of its collaborators and joint ventures as well as Harvest were variable interest entities ("VIE" or "VIEs"). The Company was not the primary beneficiary for these entities since it did not have the power to direct the activities that most significantly impact the economic performance of the VIEs. The Company's aggregate investment balances of these VIEs as of June 30, 2019 and December 31, 2018 were $20,238 and $21,219 , respectively, which represents the Company's maximum risk of loss related to the identified VIEs. Operating Leases The Company adopted Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Topic 842, Leases ("ASC 842"), effective January 1, 2019. Under ASC 842, the Company determines if an arrangement is a lease at inception. Operating leases are included as right-of-use assets ("ROU Assets") and lease liabilities on the consolidated balance sheets. The Company has elected not to recognize ROU Assets or lease liabilities for leases with lease terms of one year or less. ROU Assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. For leases that contain fixed non-lease payments, the Company accounts for the lease and non-lease components as a single lease component. Variable lease payments, which primarily include payments for non-lease components such as maintenance costs, are excluded from the ROU Assets and lease liabilities and are recognized in the period in which the obligation for those payments is incurred. As most of the Company's operating leases do not provide an implicit interest rate, the Company uses its incremental borrowing rate at the lease commencement date, which is the estimated rate the Company would be required to pay for a collateralized borrowing equal to the total lease payments over the term of the lease, in determining the present value of future payments. The initial measurement of the ROU Asset also includes any lease payments made and excludes lease incentives. The lease term for all of the Company's leases includes the noncancelable period of the lease plus any additional periods covered by options that the Company is reasonably certain to exercise, either to extend or to not terminate the lease. Lease expense is recognized on a straight-line basis over the lease term. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. Segment Information The Company realigned its business in April 2019, and as a result, its chief operating decision maker ("CODM") now regularly reviews disaggregated financial information for various operating segments. The Company's reportable segments now include (i) Precigen; (ii) the Methane Bioconversion Platform division, which is an operating division of Intrexon; (iii) the Fine Chemicals division, which is also an operating division of Intrexon; (iv) Okanagan; and (v) Trans Ova. All of Intrexon's consolidated subsidiaries and operating divisions that did not meet the quantitative thresholds to report separately are combined and reported in a single category, All Other. See Note 1 for a description of Precigen, Okanagan, and Trans Ova. Corporate expenses are not allocated to the segments and are managed at a consolidated level. The Company's segment presentation has been recast to retrospectively reflect the change from one reportable segment to multiple reportable segments. See Note 19 for further discussion of the Company's segments. Recently Adopted Accounting Pronouncements The Company adopted ASC 842 on January 1, 2019 using the modified retrospective method as of the adoption date without restating prior periods. In addition, the Company elected to use the package of practical expedients which allowed the Company to not have to reassess whether expired or existing contracts contain leases under the new definition of a lease or the lease classification for expired or existing leases under ASC Topic 840. As a result of the adoption of ASC 842, the Company recorded ROU Assets and lease liabilities of approximately $43,500 and $45,500 , respectively, as of January 1, 2019. The difference between the ROU Assets and lease liabilities primarily represents the balance of deferred rent as of December 31, 2018 that resulted from historical straight-lining of operating leases expense, which was reclassified upon adoption to reduce the measurement of the ROU Assets. In June 2018, the FASB issued Accounting Standards Update ("ASU") 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting ("ASU 2018-07"). The provisions of ASU 2018-07 expand the scope of ASC Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. The Company adopted this standard effective January 1, 2019, and there was no material impact to the accompanying consolidated financial statements. Recently Issued Accounting Pronouncements In October 2018, the FASB issued ASU 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606 ("ASU 2018-18"). The provisions of ASU 2018-18 clarify when certain transactions between collaborative arrangement participants should be accounted for under ASC Topic 606, Revenue from Contracts with Customers ("ASC 606"), and incorporates unit-of-account guidance consistent with ASC 606 to aid in this determination. The guidance is effective for annual periods and interim periods within those annual periods beginning after December 15, 2019, with early adoption permitted, and is effective for the Company for the year ending December 31, 2020. The Company is currently evaluating the impact that the implementation of this standard will have on the Company's consolidated financial statements. In October 2018, the FASB issued ASU 2018-17, Consolidation (Topic 810): Targeted Improvements to Related Party Guidance for Variable Interest Entities ("ASU 2018-17"). The provisions of ASU 2018-17 modify the guidance under ASC Topic 810 related to the evaluation of indirect interests held through related parties under common control when determining whether fees paid to decision makers and service providers are variable interests. Indirect interests held through related parties that are under common control are no longer considered to be the equivalent of direct interests in their entirety and instead should be considered on a proportional basis. This guidance more closely aligns with accounting of how indirect interests held through related parties under common control are considered for determining whether a reporting entity must consolidate a VIE. The guidance is effective for annual periods and interim periods within those annual periods beginning after December 15, 2019, with early adoption permitted, and is effective for the Company for the year ending December 31, 2020. The Company is currently evaluating the impact that the implementation of this standard will have on the Company's consolidated financial statements. In August 2018, the FASB issued ASU 2018-15, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract ("ASU 2018-15"). The provisions of ASU 2018-15 clarify the accounting for implementation costs of a hosting arrangement that is a service contract. The new standard requires an entity (customer) in a hosting arrangement that is a service contract to follow existing internal-use software guidance to determine which implementation costs to capitalize as an asset related to the service contract and which costs to expense. Capitalized implementation costs of a hosting arrangement that is a service contract should be amortized over the term of the hosting arrangement, which might extend beyond the noncancelable period if there are options to extend or terminate. ASU 2018-15 also specifies the financial statement presentation of capitalized implementation costs and related amortization, in addition to required disclosures for material capitalized implementation costs related to hosting arrangements that are service contracts. The guidance is effective for annual periods and interim periods within those annual periods beginning after December 15, 2019, with early adoption permitted, and is effective for the Company for the year ending December 31, 2020. The Company is currently evaluating the impact that the implementation of this standard will have on the Company's consolidated financial statements. In August 2018, the FASB issued ASU 2018-13, Fair Value Measurements (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurements ("ASU 2018-13"). The provisions of ASU 2018-13 modify the disclosures related to recurring and nonrecurring fair value measurements. Disclosures related to the transfer of assets between Level 1 and Level 2 hierarchies have been eliminated and various additional disclosures related to Level 3 fair value measurements have been added, modified or removed. The guidance is effective for annual periods and interim periods within those annual periods beginning after December 15, 2019, but entities are permitted to early adopt either the entire standard or only the provisions that eliminate or modify the requirements. This standard is effective for the Company for the year ending December 31, 2020. The Company is currently evaluating the impact that the implementation of this standard will have on the Company's consolidated financial statements. In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments ("ASU 2016-13") . The provisions of ASU 2016-13 modify the impairment model to utilize an expected loss methodology in place of the currently used incurred loss methodology, and requires a consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The guidance is effective for annual periods and interim periods within those annual periods beginning after December 15, 2019, with early adoption permitted, and is effective for the Company for the year ending December 31, 2020. The Company is currently evaluating the impact that the implementation of this standard will have on the Company's consolidated financial statements. In April 2019, the FASB issued ASU 2019-04, Codification Improvements to Topic 326, Financial Instruments-Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments ("ASU 2019-04"). The provisions of ASU 2019-04 clarify and improve areas of guidance related to ASU 2016-13 and ASC Topic 825, Financial Instruments ("ASC 825"). The amendments to ASU 2016-13 have the same effective date as the original ASU and are effective for the Company for the year ending December 31, 2020. The amendments to ASC 825 are effective for fiscal years beginning after December 15, 2019, with early adoption permitted, and are effective for the Company for the year ending December 31, 2020. The Company is currently evaluating the impact that the implementation of this standard will have on the Company's consolidated financial statements. |
Mergers and Acquisitions
Mergers and Acquisitions | 6 Months Ended |
Jun. 30, 2019 | |
Mergers and Acquisitions [Abstract] | |
Mergers and Acquisitions | Mergers and Acquisitions Asset Acquisition of Certain Harvest Entities In September 2018, the Company, through its wholly owned subsidiary ActoBio, issued $30,000 of convertible promissory notes to Harvest, a related party, to acquire Harvest's ownership in CRS Bio, Inc., Genten Therapeutics, Inc., and Relieve Genetics, Inc. (collectively the "Harvest entities"). The Company also received $15,500 cash in the transaction from the acquisition of the Harvest entities. Prior to the transaction, the Company held a noncontrolling interest in the Harvest entities, with a combined carrying value for all entities of $4,303 , and accounted for its ownership using the equity method of accounting. Following the transaction, the Company owns 100% of the equity interests of the Harvest entities including the rights that had been previously licensed to the Harvest entities by the Company. The Harvest entities did not meet the definition of a business and accordingly, the transaction was accounted for as an asset acquisition. By reacquiring the rights previously licensed to the Harvest entities, the Company was relieved from its obligations under the original exclusive channel collaborations ("ECCs") and therefore wrote off deferred revenue of $10,078 in September 2018 as part of the transaction. The remaining value acquired of $8,721 was considered in-process research and development related to the reacquired rights under the ECCs and expensed immediately. See Note 11 for additional discussion of the convertible promissory notes. |
Investments in Joint Ventures
Investments in Joint Ventures | 6 Months Ended |
Jun. 30, 2019 | |
Equity Method Investments and Joint Ventures [Abstract] | |
Investments in Joint Ventures | Investments in Joint Ventures Intrexon Energy Partners In March 2014, the Company and certain investors (the "IEP Investors"), including an affiliate of Third Security, LLC ("Third Security"), a related party, entered into a Limited Liability Company Agreement that governs the affairs and conduct of business of Intrexon Energy Partners, LLC ("Intrexon Energy Partners"), a joint venture formed to optimize and scale-up the Company's methane bioconversion platform ("MBP") technology for the production of certain fuels and lubricants. The Company also entered into an ECC with Intrexon Energy Partners providing exclusive rights to the Company's technology for the use in bioconversion, as a result of which the Company received a technology access fee of $25,000 while retaining a 50% membership interest in Intrexon Energy Partners. The IEP Investors made initial capital contributions, totaling $25,000 in the aggregate, in exchange for pro rata membership interests in Intrexon Energy Partners totaling 50% . In addition, Intrexon has committed to make capital contributions of up to $25,000 , and the IEP Investors, as a group and pro rata in accordance with their respective membership interests in Intrexon Energy Partners, have committed to make additional capital contributions of up to $25,000 , at the request of Intrexon Energy Partners' board of managers (the "Intrexon Energy Partners Board") and subject to certain limitations. As of June 30, 2019 , the Company's remaining commitment was $4,568 . Intrexon Energy Partners is governed by the Intrexon Energy Partners Board, which has five members. Two members of the Intrexon Energy Partners Board are designated by the Company and three members are designated by a majority of the IEP Investors. The Company and the IEP Investors have the right, but not the obligation, to make additional capital contributions above the initial limits when and if solicited by the Intrexon Energy Partners Board. The Company's investment in Intrexon Energy Partners was $(585) and $(656) as of June 30, 2019 and December 31, 2018 , respectively, and is included in other accrued liabilities in the accompanying consolidated balance sheets. Intrexon Energy Partners II In December 2015, the Company and certain investors (the "IEPII Investors"), including Harvest, entered into a Limited Liability Company Agreement that governs the affairs and conduct of business of Intrexon Energy Partners II, LLC ("Intrexon Energy Partners II"), a joint venture formed to utilize the Company's MBP technology for the production of 1,4-butanediol, an industrial chemical used to manufacture spandex, polyurethane, plastics, and polyester. The Company also entered into an ECC with Intrexon Energy Partners II that provides exclusive rights to the Company's technology for use in the field, as a result of which the Company received a technology access fee of $18,000 while retaining a 50% membership interest in Intrexon Energy Partners II. The IEPII Investors made initial capital contributions, totaling $18,000 in the aggregate, in exchange for pro rata membership interests in Intrexon Energy Partners II totaling 50% . In December 2015, the owners of Intrexon Energy Partners II made a capital contribution of $4,000 , half of which was paid by the Company. Intrexon has committed to make additional capital contributions of up to $10,000 , and the IEPII Investors, as a group and pro rata in accordance with their respective membership interests in Intrexon Energy Partners II, have committed to make additional capital contributions of up to $10,000 , at the request of Intrexon Energy Partners II's board of managers (the "Intrexon Energy Partners II Board") and subject to certain limitations. Intrexon Energy Partners II is governed by the Intrexon Energy Partners II Board, which has five members. One member of the Intrexon Energy Partners II Board is designated by the Company and four members are designated by a majority of the IEPII Investors. The Company and the IEPII Investors have the right, but not the obligation, to make additional capital contributions above the initial limits when and if solicited by the Intrexon Energy Partners II Board. The Company's investment in Intrexon Energy Partners II was $(373) and $(50) as of June 30, 2019 and December 31, 2018 , respectively, and is included in other accrued liabilities in the accompanying consolidated balance sheets. EnviroFlight In February 2016, the Company entered into a series of transactions involving EnviroFlight, LLC ("Old EnviroFlight"), Darling Ingredients Inc. ("Darling") and a newly formed venture between the Company and Darling ("New EnviroFlight"). New EnviroFlight was formed to generate high-nutrition, low environmental impact animal and fish feed, as well as fertilizer products, from black soldier fly larvae. Through June 30, 2019 , the Company and Darling have made subsequent capital contributions of $18,000 each. The Company's investment in New EnviroFlight was $15,798 and $16,720 as of June 30, 2019 and December 31, 2018 , respectively, and is included in investments in affiliates in the accompanying consolidated balance sheets. Intrexon T1D Partners In March 2016, the Company and certain investors (the "T1D Investors"), including affiliates of Third Security, entered into a Limited Liability Company Agreement that governs the affairs and conduct of business of Intrexon T1D Partners, LLC ("Intrexon T1D Partners"), a joint venture formed to utilize the Company's proprietary ActoBiotics platform to develop and commercialize products to treat type 1 diabetes. The Company also entered into an ECC with Intrexon T1D Partners that provides the exclusive rights to the Company's technology for use in the field, as a result of which the Company received a technology access fee of $10,000 while retaining a 50% membership interest in Intrexon T1D Partners. The T1D Investors made initial capital contributions, totaling $10,000 in the aggregate, in exchange for pro rata membership interests in Intrexon T1D Partners totaling 50% . Intrexon committed to make capital contributions of up to $5,000 , and the T1D Investors, as a group and pro rata in accordance with their respective membership interests in Intrexon T1D Partners, committed to make additional capital contributions of up to $5,000 , at the request of Intrexon T1D Partners' board of managers, which consisted of two members appointed by the Company and three members appointed by a majority of the T1D Investors. The Company satisfied its commitment in 2018. In November 2018, the Company, together with its wholly owned subsidiary ActoBio, issued 1,933,737 shares of Intrexon common stock valued at $18,970 to the T1D Investors to acquire their ownership interest in Intrexon T1D Partners. Following the transaction, the Company owns 100% of the membership interests in Intrexon T1D Partners, including the rights that had been previously licensed to Intrexon T1D Partners by the Company in the ECC. Intrexon T1D Partners did not meet the definition of a business, and accordingly, the transaction was accounted for as an asset acquisition. By reacquiring the rights previously licensed to Intrexon T1D Partners, the Company was relieved from its obligations under the original ECC and therefore wrote off $8,517 of deferred revenue in November 2018 as part of the transaction. The remaining value of $10,453 was considered in-process research and development related to the reacquired rights under the ECC and expensed immediately. |
Collaboration and Licensing Rev
Collaboration and Licensing Revenue | 6 Months Ended |
Jun. 30, 2019 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Collaboration and Licensing Revenue | Collaboration and Licensing Revenue The Company's collaborations and licensing agreements provide for multiple promises to be satisfied by the Company and typically include a license to the Company's technology platforms, participation in collaboration committees, and performance of certain research and development services. Based on the nature of the promises in the Company's collaboration and licensing agreements, the Company typically combines most of its promises into a single performance obligation because the promises are highly interrelated and not individually distinct. At contract inception, the transaction price is typically the upfront payment received and is allocated to the single performance obligation. The Company has determined the transaction price should be recognized as revenue based on its measure of progress under the agreement primarily based on inputs necessary to fulfill the performance obligation. The Company recognizes the reimbursement payments received for research and development services in the period when the services are performed. At the inception of each collaboration, the Company determines whether any milestone payments are probable and can be included in the transaction price. The milestone payments are typically not considered probable at inception and are therefore constrained. Royalties related to product sales will be recognized when sales have occurred since the royalties relate directly to the technology license granted in the agreement. The Company determines whether collaborations and licensing agreements are individually significant for disclosure based on a number of factors, including total revenue recorded by the Company pursuant to collaboration and licensing agreements, collaborators or licensees with either majority-owned subsidiaries or equity method investments, or other qualitative factors. Collaboration and licensing revenues generated from consolidated subsidiaries are eliminated in consolidation. The following table summarizes the amounts recorded as revenue in the consolidated statements of operations for each significant counterparty to a collaboration or licensing agreement for the three and six months ended June 30, 2019 and 2018 . Three Months Ended Six Months Ended 2019 2018 2019 2018 ZIOPHARM Oncology, Inc. $ 533 $ 3,423 $ 1,699 $ 8,800 Ares Trading S.A. — 3,526 — 5,949 Oragenics, Inc. 181 37 384 162 Intrexon T1D Partners, LLC — 703 — 2,031 Intrexon Energy Partners, LLC 796 819 1,773 2,016 Intrexon Energy Partners II, LLC 420 553 924 931 Surterra Holdings, Inc. 160 — 160 — Genopaver, LLC 398 1,072 692 2,387 Fibrocell Science, Inc. 2,462 331 2,845 624 Persea Bio, LLC 810 306 (462 ) 515 Harvest start-up entities (1) 2,039 5,904 4,762 9,101 Other 1,298 776 2,290 4,782 Total $ 9,097 $ 17,450 $ 15,067 $ 37,298 (1) For the three and six months ended June 30, 2019 and 2018 , revenues recognized from collaborations with Harvest start-up entities include: Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; and AD Skincare, Inc. For the three and six months ended June 30, 2018 , revenues recognized from collaborations with Harvest start-up entities also include Genten Therapeutics, Inc. and CRS Bio, Inc. Except for the agreements discussed below, there have been no significant changes to the agreements with our collaborators and licensees in the six months ended June 30, 2019 . Surterra Collaboration In June 2019, the Company entered into an Exclusive Product Collaboration agreement ("Surterra EPC") with Surterra Holdings, Inc. ("Surterra") to advance Surterra's cannabinoid production at a reliable, efficient, cost-effective, and industrial scale utilizing the Company's yeast fermentation platform. Upon execution of the Surterra EPC, the Company received a technology access fee in the form of a $10,000 cash payment and common stock of Surterra valued at $4,530 as upfront consideration. The Company is entitled to developmental milestones for each target selected by Surterra up to a maximum of $68,000 for the achievement of all milestones for all targets as defined in the agreement. The Company is entitled to payments for research and development services provided pursuant to the agreement as well as single-digit royalties on quarterly gross sales of products developed. The Company's performance obligations terminate upon the acceptance of all deliverables for each target selected under the agreement, and the agreement may be terminated by either party in the event of a material breach as defined in the agreement or may be terminated voluntarily by Surterra upon 90 days written notice to the Company. The Company has recorded a receivable, which is included in other noncurrent assets in the accompanying consolidated balance sheet, for the balance of common stock as of June 30, 2019, since the stock had not yet been legally issued as of that date. Fibrocell Science Collaboration In April 2019, Fibrocell Science, Inc. ("Fibrocell"), a publicly traded cell and gene therapy company focused on disease affecting the skin and connective tissue and a related party, entered into a collaboration agreement with a third party to develop and commercialize a product in the field of the Company's ECC with Fibrocell ("Fibrocell ECC"). Pursuant to the terms of the Fibrocell ECC, the Company is entitled to 50% of sublicensing fees and accordingly, has recorded a related party receivable in the accompanying consolidated balance sheet of $3,750 as of June 30, 2019. Deferred Revenue Deferred revenue primarily consists of consideration received for the Company's collaboration and licensing agreements. Deferred revenue consists of the following: June 30, December 31, Collaboration and licensing agreements $ 78,265 $ 63,284 Prepaid product and service revenues 2,523 2,933 Other 2,347 3,547 Total $ 83,135 $ 69,764 Current portion of deferred revenue $ 16,593 $ 15,554 Long-term portion of deferred revenue 66,542 54,210 Total $ 83,135 $ 69,764 The following table summarizes the remaining balance of deferred revenue associated with upfront and milestone payments for each significant counterparty to a collaboration or licensing agreement as of June 30, 2019 and December 31, 2018 , including the estimated remaining performance period as of June 30, 2019 . Average Remaining Performance Period (Years) June 30, December 31, ZIOPHARM Oncology, Inc. 0.3 $ 398 $ 1,214 Oragenics, Inc. 4.9 5,552 5,810 Intrexon Energy Partners, LLC 4.8 9,059 10,267 Intrexon Energy Partners II, LLC 5.4 13,136 14,060 Surterra Holdings, Inc. 9.0 14,500 — Genopaver, LLC 4.8 1,162 1,175 Fibrocell Science, Inc. 5.4 18,507 17,519 Persea Bio, LLC 5.5 3,839 2,697 Harvest start-up entities (1) 5.7 6,993 7,644 Other 1.8 5,028 2,898 Total $ 78,174 $ 63,284 (1) As of June 30, 2019 and December 31, 2018 , the balance of deferred revenue for collaborations with Harvest start-up entities includes: Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; and AD Skincare, Inc. |
Short-term Investments
Short-term Investments | 6 Months Ended |
Jun. 30, 2019 | |
Investments, Debt and Equity Securities [Abstract] | |
Short-term Investments | Short-term Investments The Company's investments are classified as available-for-sale. The following table summarizes the amortized cost, gross unrealized gains and losses, and fair value of available-for-sale investments as of June 30, 2019 : Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Aggregate Fair Value U.S. government debt securities $ 67,256 $ 45 $ — $ 67,301 Certificates of deposit 340 — — 340 Total $ 67,596 $ 45 $ — $ 67,641 The following table summarizes the amortized cost, gross unrealized gains and losses, and fair value of available-for-sale investments as of December 31, 2018 : Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Aggregate Fair Value U.S. government debt securities $ 119,401 $ — $ (61 ) $ 119,340 Certificates of deposit 348 — — 348 Total $ 119,749 $ — $ (61 ) $ 119,688 As of June 30, 2019 , all of the available-for-sale investments were due within one year based on their contractual maturities. Changes in market interest rates and bond yields cause certain investments to fall below their cost basis, resulting in unrealized losses on investments. The unrealized losses of the Company's investments were primarily a result of unfavorable changes in interest rates subsequent to the initial purchase of these investments and were not significant as of June 30, 2019 . As of June 30, 2019 and December 31, 2018 , the Company did not consider any of its debt security investments to be other-than-temporarily impaired. When evaluating its debt security investments for other-than-temporary impairment, the Company reviews factors such as the length of time and extent to which fair value has been below its cost basis, the financial condition of the issuer, the Company's ability and intent to hold the security and whether it is more likely than not that it will be required to sell the investment before recovery of its cost basis. |
Fair Value Measurements
Fair Value Measurements | 6 Months Ended |
Jun. 30, 2019 | |
Fair Value Disclosures [Abstract] | |
Fair Value Measurements | Fair Value Measurements The carrying amount of cash and cash equivalents, restricted cash, receivables, prepaid expenses and other current assets, accounts payable, accrued compensation and benefits, other accrued liabilities, and related party payables approximate fair value due to the short maturity of these instruments. Assets The following table presents the placement in the fair value hierarchy of financial assets that are measured at fair value on a recurring basis, including the items for which the fair value option has been elected, at June 30, 2019 : Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) June 30, Assets U.S. government debt securities $ — $ 67,301 $ — $ 67,301 Equity securities 1,196 266 20,041 21,503 Other — 468 247 715 Total $ 1,196 $ 68,035 $ 20,288 $ 89,519 The following table presents the placement in the fair value hierarchy of financial assets that are measured at fair value on a recurring basis, including the items for which the fair value option has been elected, at December 31, 2018 : Quoted Prices in Active Markets Significant Other Observable Inputs Significant Unobservable Inputs December 31, Assets U.S. government debt securities $ — $ 119,340 $ — $ 119,340 Equity securities 1,626 556 — 2,182 Other — 468 191 659 Total $ 1,626 $ 120,364 $ 191 $ 122,181 The method used to estimate the fair value of the Level 1 assets in the tables above is based on observable market data as these equity securities are publicly-traded. The method used to estimate the fair value of the Level 2 short-term investments in the tables above is based on professional pricing sources for identical or comparable instruments, rather than direct observations of quoted prices in active markets. The methods used to estimate the fair value of the Level 2 and Level 3 equity securities in the tables above are based on the quoted market price of the publicly-traded security, adjusted for any trading restrictions, including discounts for lack of marketability based on historical volatilities and the restriction period. Market price volatility of these Level 3 securities and a significant change in the assumptions used in the discount for lack of marketability could result in a significant impact to the fair value. The Company owns preferred stock in certain of its collaborators, and these investments are classified as Level 3 within the fair value hierarchy. The methods used to estimate the fair value of these Level 3 assets are discussed in Note 17 . The following table summarizes the changes in the Level 3 investments in equity securities and preferred stock during the six months ended June 30, 2019 . Six Months Ended Beginning balance $ 191 Retained interest in deconsolidated subsidiary 14,239 Dividend income from investments in preferred stock 25 Net unrealized appreciation in the fair value of the investments in equity securities and preferred stock 5,833 Ending balance $ 20,288 There were no transfers of assets between levels of the fair value hierarchy during the six months ended June 30, 2019 . Liabilities The carrying values of the Company's long-term debt, excluding the 3.50% convertible senior notes due 2023 (the "Convertible Notes"), approximates fair value due to the length of time to maturity and/or the existence of interest rates that approximate prevailing market rates. The calculated fair value of the Convertible Notes (Note 11 ) was approximately $112,000 and $141,000 as of June 30, 2019 and December 31, 2018 , respectively, and is based on the most recent third-party trade of the instrument as of the balance sheet date. The fair value of the Convertible Notes is classified as Level 2 within the fair value hierarchy as there is not an active market for the Convertible Notes, however, third-party trades of the instrument are considered observable inputs. The Convertible Notes are reflected on the accompanying consolidated balance sheets at amortized cost, which was $152,634 and $148,101 as of June 30, 2019 and December 31, 2018 , respectively. The Company's contingent consideration liabilities are measured on a recurring basis and were $585 at June 30, 2019 and December 31, 2018 . These fair value measurements were based on significant inputs not observable in the market and thus represented a Level 3 measurement. A significant change in unobservable inputs could result in a significant impact on the fair value of the Company's contingent consideration liabilities. The contingent consideration liabilities are remeasured to fair value at each reporting date until the contingencies are resolved, and those changes in fair value are recognized in earnings. There were no changes in the fair value of the Level 3 liabilities during the three and six months ended June 30, 2019 . |
Inventory
Inventory | 6 Months Ended |
Jun. 30, 2019 | |
Inventory Disclosure [Abstract] | |
Inventory | Inventory Inventory consists of the following: June 30, December 31, Supplies, embryos and other production materials $ 2,962 $ 4,729 Work in process 4,893 4,391 Livestock 9,462 10,167 Feed 875 2,160 Total inventory $ 18,192 $ 21,447 |
Property, Plant and Equipment,
Property, Plant and Equipment, Net | 6 Months Ended |
Jun. 30, 2019 | |
Property, Plant and Equipment [Abstract] | |
Property, Plant and Equipment, Net | Property, Plant and Equipment, Net Property, plant and equipment consist of the following: June 30, December 31, Land and land improvements $ 11,674 $ 12,490 Buildings and building improvements 11,590 20,371 Furniture and fixtures 1,684 1,891 Equipment 68,138 74,555 Leasehold improvements 31,925 28,289 Breeding stock 4,675 4,582 Computer hardware and software 12,131 11,697 Trees 16,141 11,910 Construction and other assets in progress 23,000 18,880 180,958 184,665 Less: Accumulated depreciation and amortization (60,557 ) (55,791 ) Property, plant and equipment, net $ 120,401 $ 128,874 The deconsolidation of AquaBounty (Note 1 ) in April 2019 resulted in the reduction of $24,186 of property, plant and equipment, net on the accompanying consolidated balance sheet as of June 30, 2019 . During the three and six months ended June 30, 2018, the Company recorded a $4,972 loss on disposal of certain leasehold improvements, equipment, and other fixed assets, in conjunction with the closing of one of its research and development facilities in Brazil. Depreciation expense was $3,347 and $3,642 for the three months ended June 30, 2019 and 2018 , respectively, and $6,920 and $7,098 for the six months ended June 30, 2019 and 2018 , respectively. |
Goodwill and Intangible Assets,
Goodwill and Intangible Assets, Net | 6 Months Ended |
Jun. 30, 2019 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Goodwill and Intangible Assets, Net | Goodwill and Intangible Assets, Net The changes in the carrying amount of goodwill for the six months ended June 30, 2019 are as follows: Balance at December 31, 2018 $ 149,585 Foreign currency translation adjustments 331 Balance at June 30, 2019 $ 149,916 The Company had $13,823 of accumulated impairment losses as of June 30, 2019 and December 31, 2018 . In April 2019, as a result of the Company's change in segments (Notes 2 and 19 ), the Company concluded that certain operating segments are now separate reporting units. Accordingly, the Company performed a relative fair value allocation of certain of its goodwill. Intangible assets consist of the following as of June 30, 2019 : Gross Carrying Amount Accumulated Amortization Net Patents, developed technologies and know-how $ 139,363 $ (37,251 ) $ 102,112 Customer relationships 10,700 (8,002 ) 2,698 Trademarks 5,900 (3,514 ) 2,386 In-process research and development 5,330 — 5,330 Total $ 161,293 $ (48,767 ) $ 112,526 Intangible assets consist of the following as of December 31, 2018 : Gross Carrying Amount Accumulated Amortization Net Patents, developed technologies and know-how $ 152,482 $ (35,133 ) $ 117,349 Customer relationships 10,700 (7,565 ) 3,135 Trademarks 6,800 (3,341 ) 3,459 In-process research and development 5,348 — 5,348 Total $ 175,330 $ (46,039 ) $ 129,291 The balance of in-process research and development includes certain in-process research and development technology acquired in the Company's acquisition of Oxitec in September 2015, and amortization will begin once certain regulatory approvals have been obtained for the in-process programs. The deconsolidation of AquaBounty (Note 1 ) in April 2019 resulted in the reduction of $11,567 of net intangible assets, primarily related to patents, developed technologies, and know-how, on the accompanying consolidated balance sheet as of June 30, 2019 . Amortization expense was $2,766 and $4,857 for the three months ended June 30, 2019 and 2018 , respectively, and $5,770 and $9,783 for the six months ended June 30, 2019 and 2018 , respectively. |
Lines of Credit and Long-Term D
Lines of Credit and Long-Term Debt | 6 Months Ended |
Jun. 30, 2019 | |
Debt Disclosure [Abstract] | |
Lines of Credit and Long-Term Debt | Lines of Credit and Long-Term Debt Lines of Credit Trans Ova has an $8,000 revolving line of credit with First National Bank of Omaha that matures on December 31, 2019. The line of credit bears interest at the greater of 2.95% above the London Interbank Offered Rate or 3.00% , and the actual rate was 5.37% as of June 30, 2019 . As of June 30, 2019 , there was no outstanding balance. The amount available under the line of credit is based on eligible accounts receivable and inventory up to the maximum principal amount. The line of credit is collateralized by certain of Trans Ova's assets and contains certain restricted covenants that include maintaining minimum tangible net worth and working capital and maximum allowable annual capital expenditures. Trans Ova was in compliance with these covenants as of June 30, 2019 . Exemplar has a $700 revolving line of credit with American State Bank that matures on October 30, 2019. The line of credit bears interest at 5.75% per annum. As of June 30, 2019 , there was an outstanding balance of $387 . Long-Term Debt Long-term debt consists of the following: June 30, December 31, Convertible debt $ 208,376 $ 203,391 Notes payable 4,320 4,551 Other 251 3,852 Long-term debt 212,947 211,794 Less current portion 468 559 Long-term debt, less current portion $ 212,479 $ 211,235 The deconsolidation of AquaBounty (Note 1 ) in April 2019 resulted in the reduction of $4,030 of long-term debt on the accompanying consolidated balance sheet as of June 30, 2019 . Convertible Debt Intrexon Convertible Notes In July 2018, Intrexon completed a registered underwritten public offering of $200,000 aggregate principal amount of Convertible Notes and issued the Convertible Notes under an indenture (the "Base Indenture") between Intrexon and The Bank of New York Mellon Trust Company, N.A., as trustee, as supplemented by the First Supplemental Indenture (together with the Base Indenture, the "Indenture"). Intrexon received net proceeds of $193,958 after deducting underwriting discounts and offering expenses of $6,042 . The Convertible Notes are senior unsecured obligations of Intrexon and bear interest at a rate of 3.50% per year, payable semiannually in arrears on January 1 and July 1 of each year beginning on January 1, 2019. The Convertible Notes mature on July 1, 2023, unless earlier repurchased or converted. The Convertible Notes are convertible into cash, shares of Intrexon's common stock or a combination of cash and shares, at Intrexon's election. The initial conversion rate of the Convertible Notes is 58.6622 shares of Intrexon common stock per $1,000 principal amount of Convertible Notes (equivalent to an initial conversion price of approximately $17.05 per share of common stock). The conversion rate is subject to adjustment upon the occurrence of certain events, but will not be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the maturity date as defined in the Indenture, Intrexon will increase the conversion rate for a holder who elects to convert its Convertible Notes in connection with such a corporate event in certain circumstances. Prior to April 1, 2023, the holders may convert the Convertible Notes at their option only upon the satisfaction of the following circumstances: • During any calendar quarter commencing after the calendar quarter ending on September 30, 2018, if the last reported sales price of Intrexon's common stock for at least 20 trading days (whether or not consecutive) during the last 30 consecutive trading days of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day; • During the five business day period after any five consecutive trading day period in which the trading price, as defined in the Indenture, for the Convertible Notes is less than 98% of the product of the last reported sales price of Intrexon's common stock and the conversion rate for the Convertible Notes on each such trading day; or • Upon the occurrence of specified corporate events as defined in the Indenture. None of the above events allowing for conversion prior to April 1, 2023 occurred during the three months ended June 30, 2019 . On or after April 1, 2023 until June 30, 2023, holders may convert their Convertible Notes at any time. Intrexon may not redeem the Notes prior to the maturity date. If Intrexon undergoes a fundamental change, as defined in the Indenture, holders of the Convertible Notes may require Intrexon to repurchase for cash all or any portion of their Convertible Notes at a fundamental change repurchase price equal to 100% of the principal amount of the Convertible Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The Indenture contains customary events of default, as defined in the agreement, and, if any of the events occur, could require repayment of a portion or all of the Convertible Notes, including accrued and unpaid interest. Additionally, the Indenture provides that Intrexon shall not consolidate with or merge with or into, or sell, convey, transfer or lease all or substantially all of its properties and assets to, another entity, unless (i) the surviving entity is organized under the laws of the United States and such entity expressly assumes all of Intrexon's obligations under the Convertible Notes and the Indenture; and (ii) immediately after such transaction, no default or event of default has occurred and is continuing under the Indenture. The net proceeds received from the issuance of the Convertible Notes were initially allocated between long-term debt, the liability component, at $143,723 and additional paid-in capital, the equity component, at $50,235 . Additional paid-in capital was further reduced by $13,367 of deferred taxes resulting from the difference between the carrying amount and the tax basis of the Convertible Notes that is created by the equity component, which resulted in deferred tax benefit recognized from the reversal of valuation allowances on the then current year domestic operating losses in the same amount. As of June 30, 2019 , the outstanding principal balance on the Convertible Notes was $200,000 and the carrying value of long-term debt was $152,634 . The effective interest rate on the Convertible Notes, including amortization of the long-term debt discount and debt issuance costs, is 11.02% . As of June 30, 2019 , the unamortized long-term debt discount and debt issuance costs totaled $47,366 . Total interest expense related to the Convertible Notes was $4,069 and $8,032 for the three and six months ended June 30, 2019 , respectively, which consists of $1,750 and $3,500 cash interest expense, respectively, and $2,319 and $4,532 of non-cash interest expense, respectively. The cash interest expense was paid in June 2019. ActoBio Convertible Notes In September 2018, ActoBio issued $30,000 of convertible promissory notes (the "ActoBio Notes") to a related party in conjunction with an asset acquisition with Harvest (Note 3 ). The ActoBio Notes have a maturity date of September 6, 2020, accrue interest at 3.0% compounded annually, are convertible into shares of ActoBio common stock at any time by the holder, and are automatically convertible in shares of ActoBio common stock upon the closing of certain financing events as defined in the ActoBio Notes. If the ActoBio Notes have not been converted to ActoBio common stock by the maturity date, ActoBio can pay the principal and accrued interest in cash or with shares of Intrexon common stock at its election. There are no embedded features that are required to be separated from the debt host and accounted for separately, so the ActoBio Notes were recorded at $30,000 . Interest expense for the three and six months ended June 30, 2019 was $228 and $453 , respectively. As of June 30, 2019 , the carrying value of the ActoBio Notes, including accrued interest, was $30,743 . Intrexon and Precigen Convertible Note In December 2018, in conjunction with the Securities Purchase, Assignment and Assumption Agreement with Ares Trading S.A. ("Ares Trading"), Intrexon and Precigen jointly and severally issued a $25,000 convertible note (the "Merck Note") to Ares Trading in exchange for cash. The Merck Note has a maturity date of June 28, 2021 and will be converted to Intrexon common stock on the first trading day following maturity if not otherwise converted prior to that date. Prior to maturity, Ares Trading may convert the Merck Note, at their election, into (i) Intrexon common stock at any time, (ii) Intrexon common stock upon the Company's closing of qualified financing as defined in the agreement, (iii) Precigen equity upon Precigen closing a qualified financing as defined in the agreement, and (iv) Precigen common stock upon the closing of a qualified initial public offering ("IPO") of Precigen common stock. In the event of a conversion upon a qualified IPO, the conversion price will be 90% of the IPO price. In the event Ares Trading elects to convert the Merck Note into Precigen equity, the Merck Note accrues interest at a rate of 5% per year ("PIK interest") and will be converted with the outstanding principal. The Company determined that the potential PIK interest and IPO conversion discount represented embedded derivatives requiring bifurcation from the debt host but had no significant value as of June 30, 2019 and December 31, 2018 . Notes Payable Trans Ova has a note payable to American State Bank that matures in April 2033 and had an outstanding principal balance of $4,281 as of June 30, 2019 . Trans Ova pays monthly installments of $39 , which includes interest at 3.95% . The note payable is collateralized by certain of Trans Ova's real estate and non-real estate assets. Future Maturities Future maturities of long-term debt are as follows: 2019 $ 241 2020 31,254 2021 25,329 2022 339 2023 200,353 2024 366 Thereafter 2,431 Total $ 260,313 |
Income Taxes
Income Taxes | 6 Months Ended |
Jun. 30, 2019 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | Income Taxes Tax provisions for interim periods are calculated using an estimate of actual taxable income or loss for the respective period, rather than estimating the Company's annual effective income tax rate, as the Company is currently unable to reliably estimate its income for the full year. For the three and six months ended June 30, 2019 , the Company had U.S. taxable loss of approximately $55,700 and $147,300 , respectively. For the three and six months ended June 30, 2019 , the Company recognized $52 and $122 , respectively, of current foreign income tax benefit. For the three and six months ended June 30, 2018 , the Company had U.S. taxable loss of approximately $30,200 and $65,300 , respectively, and recorded $0 and $113 , respectively, of current domestic income tax expense. For the three and six months ended June 30, 2018 , the Company recognized $112 and $237 , respectively, of current foreign income tax benefit. For the three and six months ended June 30, 2019 , the Company recorded deferred tax benefit of $473 and $981 , respectively. For the three and six months ended June 30, 2018 , the Company recorded deferred tax benefit of $1,015 and $5,089 , respectively. The Company's net deferred tax assets, excluding certain deferred tax liabilities totaling $6,332 , are offset by a valuation allowance due to the Company's history of net losses combined with an inability to confirm recovery of the tax benefits of the Company's losses and other net deferred tax assets. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. As of June 30, 2019 , the Company has operating and capital loss carryforwards for U.S. federal income tax purposes of approximately $516,400 available to offset future taxable income, including approximately $263,900 generated after 2017, and federal and state research and development tax credits of approximately $8,800 , prior to consideration of annual limitations that may be imposed under Section 382 of the Internal Revenue Code of 1986, as amended. Carryforwards generated prior to 2018 begin to expire in 2022. As of June 30, 2019 , the Company's foreign subsidiaries have foreign loss carryforwards of approximately $162,900 , most of which do not expire. |
Shareholders' Equity
Shareholders' Equity | 6 Months Ended |
Jun. 30, 2019 | |
Equity [Abstract] | |
Shareholders' Equity | Shareholders' Equity Issuances of Intrexon Common Stock In January 2018, Intrexon closed a public offering of 6,900,000 shares of its common stock, including 1,000,000 shares of common stock purchased by affiliates of Third Security. The net proceeds of the offering were $82,374 , after deducting underwriting discounts of $3,688 and offering expenses of $188 , all of which were capitalized. Share Lending Agreement Concurrently with the offering of the Convertible Notes (Note 11 ), Intrexon entered into a share lending agreement (the "Share Lending Agreement") with J.P. Morgan Securities LLC (the "Share Borrower") pursuant to which Intrexon loaned and delivered 7,479,431 shares of its common stock (the "Borrowed Shares") to the Share Borrower. The Share Lending Agreement will terminate, and the Borrowed Shares will be returned to Intrexon within five business days of such termination, upon (i) termination by the Share Borrower or (ii) the earliest to occur of (a) October 1, 2023 and (b) the date, if any, on which the Share Lending Agreement is either mutually terminated or terminated by one party upon a default by the other party. The Borrowed Shares were offered and sold to the public at a price of $13.37 per share under a registered offering (the "Borrowed Shares Offering"). Intrexon did not receive any proceeds from the sale of the Borrowed Shares to the public. The Share Borrower or its affiliates received all the proceeds from the sale of the Borrowed Shares to the public. Affiliates of Third Security purchased all of the shares of common stock in the Borrowed Shares Offering. The Share Lending Agreement was entered into at fair value and met the requirements for equity classification. Therefore, the value is netted against the issuance of the Borrowed Shares in additional paid-in capital. Additionally, the Borrowed Shares are not included in the denominator for loss per share attributable to Intrexon shareholders unless the Share Borrower defaults on the Share Lending Agreement. Issuances of AquaBounty Common Stock In March 2019, AquaBounty completed an underwritten public offering that resulted in net proceeds of $6,611 after deducting discounts, fees, and expenses. See Note 1 for additional discussion of issuances of AquaBounty common stock in April 2019, which resulted in the deconsolidation of AquaBounty. In January 2018, AquaBounty completed an underwritten public offering that resulted in net proceeds of $10,616 after deducting discounts, fees and expenses. As part of this offering, Intrexon purchased $5,000 of additional AquaBounty common stock. In October 2018, certain investors exercised warrants acquired from the January 2018 offering, resulting in additional net proceeds of $4,316 , including $3,077 from Intrexon. Components of Accumulated Other Comprehensive Loss The components of accumulated other comprehensive loss are as follows: June 30, December 31, Unrealized gain (loss) on investments $ 45 $ (61 ) Loss on foreign currency translation adjustments (28,251 ) (28,551 ) Total accumulated other comprehensive loss $ (28,206 ) $ (28,612 ) |
Share-Based Payments
Share-Based Payments | 6 Months Ended |
Jun. 30, 2019 | |
Share-based Payment Arrangement [Abstract] | |
Share-Based Payments | Share-Based Payments The Company records the fair value of stock options and restricted stock units ("RSUs") issued to employees and nonemployees as of the grant date as stock-based compensation expense. Stock-based compensation expense for employees and nonemployees is recognized over the requisite service period, which is typically the vesting period. Stock-based compensation costs included in the consolidated statements of operations are presented below: Three Months Ended Six Months Ended 2019 2018 2019 2018 Cost of products $ 4 $ 25 $ 12 $ 50 Cost of services 52 79 117 156 Research and development 1,882 2,376 3,727 5,634 Selling, general and administrative (1,877 ) 6,366 5,259 14,368 Total $ 61 $ 8,846 $ 9,115 $ 20,208 Intrexon Stock Option Plans In April 2008, Intrexon adopted the 2008 Equity Incentive Plan (the "2008 Plan") for employees and nonemployees pursuant to which Intrexon's board of directors granted share based awards, including stock options, to officers, key employees and nonemployees. Upon the effectiveness of the 2013 Omnibus Incentive Plan (the "2013 Plan"), no new awards may be granted under the 2008 Plan. As of June 30, 2019 , there were 393,098 stock options outstanding under the 2008 Plan. Intrexon adopted the 2013 Plan for employees and nonemployees pursuant to which Intrexon's board of directors may grant share based awards, including stock options and shares of common stock, to employees, officers, consultants, advisors, and nonemployee directors. The 2013 Plan became effective in August 2013, and as of June 30, 2019 , there were 25,000,000 shares authorized for issuance under the 2013 Plan, of which 11,337,856 stock options and 2,271,277 RSUs were outstanding and 6,397,402 shares were available for grant. In April 2019, Intrexon adopted the Intrexon Corporation 2019 Incentive Plan for Non-Employee Service Providers (the "2019 Plan"), which became effective upon shareholder approval in June 2019. The 2019 Plan permits the grant of share based awards, including stock options, restricted stock awards, and RSUs, to non-employee service providers, including board members. As of June 30, 2019 , there were 5,000,000 shares authorized for issuance under the 2019 Plan, of which 4,853,513 were available for grant. Stock option activity was as follows: Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Balances at December 31, 2018 11,093,063 $ 27.95 6.81 Granted 1,433,075 6.46 Exercised (17,811 ) (3.17 ) Forfeited (634,204 ) (35.36 ) Expired (143,169 ) (28.38 ) Balances at June 30, 2019 11,730,954 24.96 5.75 Exercisable at June 30, 2019 8,179,447 28.82 4.52 RSU activity was as follows: Number of Restricted Stock Units Weighted Average Grant Date Fair Value Weighted Average Remaining Contractual Term (Years) Balances at December 31, 2018 970,341 $ 13.82 1.43 Granted 2,278,460 6.59 Vested (765,112 ) (9.75 ) Forfeited (212,412 ) (9.20 ) Balances at June 30, 2019 2,271,277 8.37 1.49 Intrexon currently uses authorized and unissued shares to satisfy share award exercises. The Company's Chief Executive Officer ("CEO") receives a base salary of $200 per month payable in fully-vested shares of Intrexon common stock with such shares subject to a three -year lock-up on resale. The monthly number of shares of common stock was calculated based on the closing price on the last trading day of each month and the shares were issued pursuant to the terms of a Restricted Stock Unit Agreement ("RSU Agreement") between Intrexon and the CEO pursuant to the terms of the 2013 Plan. The RSU Agreement, which is subject to renewal annually by the compensation committee of the board of directors of the Company, expired March 31, 2019. In April 2019, the Company entered into a new RSU agreement with its CEO through March 31, 2020. Under the new RSU agreement, the base salary and lock-up terms remained unchanged from the original RSU Agreement. However, the number of fully-vested shares of Intrexon common stock paid monthly will be calculated based on the volume weighted average of the price of Intrexon common stock over the 30 day period ending on the last calendar day of each month. The fair value of the shares issued as compensation for services is included in selling, general and administrative expenses in the Company's consolidated statements of operations and totaled $495 and $483 for the three months ended June 30, 2019 and 2018 , respectively, and $981 and $969 for the six months ended June 30, 2019 and 2018 , respectively. |
Operating Leases
Operating Leases | 6 Months Ended |
Jun. 30, 2019 | |
Leases [Abstract] | |
Operating Leases | Operating Leases The Company leases certain facilities and equipment under operating leases. Leases with a lease term of twelve months or less are not recorded on the balance sheet, and expense for these leases is recognized over the term of the lease. The Company's leases have remaining terms of one to twenty years , some of which may include options to extend the lease and some of which may include options to terminate the lease within one year . The leases are renewable at the option of the Company and do not contain residual value guarantees, covenants, or other restrictions. The Company's finance leases are not material. The components of lease costs were as follows: Three Months Ended Six Months Ended 2019 2019 Operating lease costs $ 2,522 $ 5,048 Short-term and variable lease costs 1,120 2,168 Lease costs $ 3,642 $ 7,216 Maturities of lease liabilities as of June 30, 2019 were as follows: 2019 $ 4,352 2020 10,088 2021 9,445 2022 8,646 2023 7,274 2024 7,139 Thereafter 26,746 Total 73,690 Present value adjustment (30,120 ) Total $ 43,570 Current portion of operating lease liabilities $ 4,813 Long-term portion of operating lease liabilities 38,757 Total $ 43,570 Other information related to operating leases was as follows: Six Months Ended 2019 Supplemental Cash Flows Information Cash paid for operating lease liabilities $ 4,929 Operating lease right-of-use assets added in exchange for new lease liabilities 1,125 June 30, Weighted average remaining lease term (years) 8.98 Weighted average discount rate 11.35 % As of June 30, 2019 , the Company had an additional operating lease commitment that had not yet commenced of approximately $1,400 with a lease term of three years . At December 31, 2018 , future minimum lease payments under operating leases having initial or remaining noncancelable lease terms in excess of one year were as follows: 2019 $ 9,182 2020 9,910 2021 9,127 2022 8,305 2023 7,229 Thereafter 34,157 Total $ 77,910 |
Commitments and Contingencies
Commitments and Contingencies | 6 Months Ended |
Jun. 30, 2019 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | Commitments and Contingencies Purchase Commitments As of June 30, 2019 , the Company had outstanding contractual purchase commitments of $10,384 , which primarily relate to amounts to be paid in 2019, 2020, and 2021 upon delivery of commercial non-browning apple trees. Contingencies In March 2012, Trans Ova was named as a defendant in a licensing and patent infringement suit brought by XY, LLC ("XY") alleging that certain of Trans Ova's sale of semen-sorting products and services breached a 2004 licensing agreement and infringed on patents related to semen sorting that XY allegedly owned. Trans Ova filed a number of counterclaims in the case. The matter proceeded to a jury trial in the United States District Court for the District of Colorado in January 2016. The jury determined that XY and Trans Ova had each breached the licensing agreement and that Trans Ova had infringed XY's patents. In April 2016, the court issued its post-trial order, awarding $528 in damages to Trans Ova and $6,066 in damages to XY. The order also provided Trans Ova with the ability to continue to practice XY's technology, subject to an ongoing royalty obligation of 12.5% of gross proceeds on Trans Ova's standard sorted semen products, plus a 2% enhancement on those products utilizing "reverse-sorted semen", or semen that is frozen before being sorted. In addition, the court assigned a $5.00 minimum royalty for a straw of sexed semen. Both parties appealed the district court's order. In May 2018, the Court of Appeals for the Federal Circuit denied Trans Ova's appeal of its claims for antitrust, breach of contract, and patent invalidity (except as to one patent, for which the Federal Circuit affirmed invalidity in a separate, same-day ruling in a third-party case). The Federal Circuit remanded the district court's calculation of the ongoing royalty and instructed the district court to re-calculate the ongoing royalty in light of post-verdict economic factors. In March 2019, the district court clarified the royalty base and reset the royalty rates consistent with the Federal Circuit opinion. The district court increased the royalty rate on Trans Ova's standard sorted semen products to 18.75% . For the reverse-sort enhancement, however, it applied a weighted, blended royalty of 12.63% to Trans Ova's entire in vitro fertilization service cycle that utilizes reverse-sorted semen. The district court also changed the minimum royalty for a straw of sexed semen to $6.25 for a 2-million cell straw (prorated appropriately for straws of higher cell counts), and assigned a minimum royalty for a sexed embryo at $6.25 per embryo. The new royalty rates are retroactive to February 2016 (the end date of the trial). Since the inception of the 2004 licensing agreement, Trans Ova has remitted payments to XY pursuant to the terms of that agreement, or pursuant to the terms of the district court's April 2016 post-trial order, and has recorded these payments in cost of services in the consolidated statements of operations for the respective periods. For the period from inception of the 2004 agreement through the district court's April 2016 order, aggregate royalty and license payments were $3,170 , of which $2,759 had not yet been deposited by XY. In 2016, the Company recorded the expense of $4,228 , representing the excess of the net damages awarded to XY, including prejudgment interest, over the liability previously recorded by Trans Ova for uncashed checks previously remitted to XY. In August 2016, Trans Ova deposited the net damages amount, including prejudgment interest, into the district court's registry, to be held until the appeals process was complete and final judgment amounts were determined. These amounts are included in restricted cash and other accrued liabilities on the consolidated balance sheet as of December 31, 2018. After the appeal, the district court subsequently released the funds held in its registry to XY in January 2019. As for post-trial damages, Trans Ova continued to remit payment to XY every quarter based on the original ongoing royalty rates set by the district court, though XY refused to cash those checks. Under the district court's March 2019 order clarifying the royalty base and resetting the royalty rates, Trans Ova recalculated royalties owed from February 2016 through the first quarter of 2019, plus any applicable pre- and post-judgment interest, and remitted that payment, totaling $5,801 , to XY in May 2019. In June 2019, XY deposited the $5,801 into the district court's registry while the parties resolve a dispute over the appropriate calculation of royalties. In that dispute, which is pending before the district court, XY filed a motion claiming over $1,000 in additional back royalties. Trans Ova is seeking an oral hearing and contends that no additional back royalties are due. During the three and six months ended June 30, 2019 , the Company recorded additional royalty expense of $267 and $383 , respectively, based on the recalculation of royalties owed XY from February 2016 through December 2018. These amounts are included in selling, general and administrative expenses on the accompanying consolidated statements of operations. In December 2016, XY filed a complaint for patent infringement, trade secret misappropriation, and various state law claims against Trans Ova in the United States District Court for the Western District of Texas in Waco, Texas. Since the claims in the 2016 complaint directly relate to the parties' other litigation, Trans Ova filed and was granted a motion to transfer the case to Colorado district court. That court subsequently dismissed nine of the complaint's twelve counts, including all five non-patent counts. The court subsequently dismissed another patent count after ruling that the patent was invalid, leaving only two patent counts left in the case. In February 2019, a Wisconsin district court invalidated one of the remaining patents, which XY had asserted against another competitor. That ruling prompted the Colorado district court to stay the two remaining patent counts and enter final judgment against XY's ten other dismissed counts. The 2016 litigation is administratively closed, pending XY's appeal of the district court's rulings dismissing its various patent and non-patent causes of action. Trans Ova shall continue to utilize the technology consistent with the determinations of the court proceedings. Nonetheless, these disputes remain subject to a number of uncertainties, including the outcome of appellate proceedings, the possibility of further claims by XY, and the impact of these matters on Trans Ova's ability to utilize the technology. Trans Ova and the Company could elect to enter into a settlement agreement in order to avoid the further costs and uncertainties of litigation. The Company may become subject to other claims, assessments, and governmental investigations from time to time in the ordinary course of business. Such matters are subject to many uncertainties and outcomes are not predictable with assurance. The Company accrues liabilities for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. As of June 30, 2019 , the Company does not believe that any such matters, individually or in the aggregate, will have a material adverse effect on the Company's business, financial condition, results of operations, or cash flows. |
Related Party Transactions
Related Party Transactions | 6 Months Ended |
Jun. 30, 2019 | |
Related Party Transactions [Abstract] | |
Related Party Transactions | Related Party Transactions Third Security and Affiliates The Company's CEO and Chairman of the board of directors is also the Senior Managing Director and CEO of Third Security and owns 100% of the equity interests of Third Security. In November 2015, the independent members of Intrexon's board of directors, with the recommendation of the audit committee of the board of directors, approved the execution of a Services Agreement ("Services Agreement") with Third Security pursuant to which Third Security provides the Company with certain professional, legal, financial, administrative, and other support services necessary to support the Company and its CEO. The Services Agreement provides for a term of one year , can be terminated by the Company at any time, and may be extended only by agreement of the parties, including approval of a majority of the independent members of Intrexon's board of directors. The independent members of Intrexon's board of directors, with the recommendation of the audit committee of the board of directors, subsequently approved extensions of the Services Agreement through January 1, 2020. Under the Services Agreement, as consideration for providing these services, Third Security is entitled to a fee of $800 per month to be paid in the form of fully-vested shares of Intrexon common stock. Through 2018, the number of shares of common stock was calculated based on the closing price of the Company's common stock on the 15th day of each month. Beginning in 2019, the number of shares of common stock is calculated based on the volume weighted average of the closing price of the Company's common stock over the 30-day period ending on the 15th day of the calendar month when the applicable services are provided. Through May 2019, the payments made by the Company under the Services Agreement constitute, in the aggregate, an award under the 2013 Plan and are subject to the terms of the 2013 Plan. Following the effectiveness of the 2019 Plan in June 2019, subsequent payments made by the Company under the Services Agreement constitute, in the aggregate, an award under the 2019 Plan and are subject to the terms of the 2019 Plan (Note 14 ). For the three months ended June 30, 2019 and 2018 , the Company issued 483,279 shares and 139,691 shares, respectively, with values of $2,284 and $2,064 , respectively, to Third Security as payment for services pursuant to the Services Agreement. For the six months ended June 30, 2019 and 2018 , the Company issued 839,993 shares and 300,317 shares, respectively, with values of $4,362 and $4,105 , respectively, to Third Security as payment for services pursuant to the Services Agreement. In addition to the foregoing Services Agreement, the Company reimburses Third Security for certain out-of-pocket expenses incurred on the Company's behalf, and the total expenses incurred by the Company under this arrangement were $1 and $3 for the three months ended June 30, 2019 and 2018 , respectively, and $18 and $17 for the six months ended June 30, 2019 and 2018 , respectively. See also Note 14 regarding compensation arrangements between the Company and its CEO. The Company also subleases certain administrative offices to Third Security. The significant terms of the lease mirror the terms of the Company's lease with the landlord, and the Company recorded sublease income of $22 and $23 for the three months ended June 30, 2019 and 2018 , respectively, and $44 for the six months ended June 30, 2019 and 2018 . Transactions with ECC Parties In addition to entities controlled by Third Security, entities in which the Company holds more than a de minimis equity interest, including equity securities received as upfront or milestone consideration, and that also are party to a collaboration with the Company are considered to be related parties. In June 2016, the Company received 100,000 shares of Series 1 Preferred Stock (the "Preferred Shares") of ZIOPHARM Oncology, Inc. ("ZIOPHARM"), with a per share stated value of $1,200 , as consideration for amending their two previously existing ECC agreements. The Company received a monthly dividend, paid in additional Preferred Shares, equal to $12.00 per Preferred Share held per month divided by the stated value of the Preferred Shares. In conjunction with the reacquisition of certain rights previously licensed to ZIOPHARM in October 2018, the Company returned to ZIOPHARM all of the Preferred Shares owned or accrued by the Company as of the effective date of the agreement. During the three and six months ended June 30, 2018 , the Company received an additional 3,734 and 7,358 Preferred Shares, respectively, and recognized $5,019 and $9,890 of dividend income in the accompanying consolidated statement of operations, respectively. Following the transaction in October 2018, ZIOPHARM is no longer considered a related party. In March 2017, Fibrocell sold Series A Convertible Preferred Stock (the "Convertible Preferred Shares"), convertible into shares of Fibrocell common stock, and warrants to purchase shares of Fibrocell common stock to certain institutional and accredited investors, including the Company and affiliates of Third Security. The Company paid $1,161 in exchange for 1,161 Convertible Preferred Shares and warrants to acquire 99,769 shares of Fibrocell common stock. The Convertible Preferred Shares are convertible at any time at the election of the Company and accrue dividends at 4% per annum, compounded quarterly, increasing the stated value of the shares. The investment in Fibrocell preferred stock is categorized as Level 3 as there are significant unobservable inputs and the Convertible Preferred Shares are not traded on a public exchange. The fair value of the investment in Fibrocell preferred stock is estimated using a conversion plus dividend approach utilizing the trading value of the underlying common stock and an estimated premium for the preferred stock dividend and other preferences. Market price volatility of Fibrocell's common stock and a significant change in the estimated preferred stock premium could result in a significant impact to the fair value of the investment in Fibrocell preferred stock. As of June 30, 2019 and December 31, 2018 , the fair value of the Company's investment in Fibrocell preferred stock totaled $247 and $191 , respectively, and is included in other assets on the accompanying consolidated balance sheets. The Company also holds a promissory note convertible into shares of Fibrocell common stock ("convertible note") and additional warrants to purchase shares of Fibrocell common stock. As of June 30, 2019 and December 31, 2018 , the value of the convertible note and warrants totaled $128 and $120 , respectively, and is included in other assets on the accompanying consolidated balance sheets. In November 2017, concurrent with Oragenics closing a preferred stock private placement, the Company exchanged a promissory note, including accrued interest, purchased from Oragenics in May 2017 and receivables due from Oragenics totaling $3,385 for Oragenics Series C preferred stock ("Series C Preferred Stock"). The Series C Preferred Stock is non-voting and non-convertible and is redeemable in whole or part at any time by Oragenics in cash. The Series C Preferred Stock accrued an annual 12% dividend payable in additional Series C Preferred Stock through May 10, 2019, and after such date, the annual dividend increased to 20% . As of June 30, 2019 and December 31, 2018 , based on the most recent financial information available on Oragenics, the Company concluded that there was no value to its investment in Oragenics preferred stock. During 2018, the Company mutually terminated each of its ECC agreements with Histogenics Corporation, OvaScience, Inc., and Synthetic Biologics, Inc. Upon termination of these ECCs, the Company recognized the remaining deferred revenue totaling $11,877 , including $3,183 during the six months ended June 30, 2018 . |
Net Loss per Share
Net Loss per Share | 6 Months Ended |
Jun. 30, 2019 | |
Earnings Per Share [Abstract] | |
Net Loss per Share | Net Loss per Share The following table presents the computation of basic and diluted net loss per share: Three Months Ended Six Months Ended 2019 2018 2019 2018 Historical net loss per share: Numerator: Net loss attributable to Intrexon $ (38,766 ) $ (65,382 ) $ (99,475 ) $ (111,547 ) Denominator: Weighted average shares outstanding, basic and diluted 153,749,929 129,299,584 153,351,208 128,500,897 Net loss attributable to Intrexon per share, basic and diluted $ (0.25 ) $ (0.51 ) $ (0.65 ) $ (0.87 ) The following potentially dilutive securities as of June 30, 2019 and 2018 , have been excluded from the above computations of diluted weighted average shares outstanding for the three and six months then ended as they would have been anti-dilutive: June 30, 2019 2018 Convertible debt 19,667,765 — Options 11,730,954 11,359,531 Restricted stock units 2,271,277 1,033,084 Warrants 133,264 133,264 Total 33,803,260 12,525,879 |
Segments Segments
Segments Segments | 6 Months Ended |
Jun. 30, 2019 | |
Segment Reporting [Abstract] | |
Segments | Segments Through March 31, 2019, the Company was a single operating segment. In April 2019, the Company initiated efforts to better deploy resources, realize inherent synergies, and position the Company for growth with a core focus on healthcare and initiated plans to achieve this through various corporate activities, including partnering, potential asset sales, and operating cost reductions. Thereafter, the Company's CODM assessed the operating performance of and allocated resources for several operating segments using Segment Adjusted EBITDA. Management believes this financial metric is a key indicator of operating results since it excludes noncash revenues and expenses that are not reflective of the underlying business performance of an individual enterprise. The Company defines Segment Adjusted EBITDA as net loss before (i) interest expense, (ii) income tax expense or benefit, (iii) depreciation and amortization, (iv) stock-based compensation expense, (v) loss on impairment of goodwill and other long-lived assets, (vi) equity in net loss of affiliates, and (vii) recognition of previously deferred revenue associated with upfront and milestone payments as well as cash outflows from capital expenditures and investments in affiliates. Because the Company uses Segment Adjusted EBITDA as its primary measure of segment performance, it has included this measure in its discussion of segment operating results. The Company has also disclosed revenues from external customers and intersegment revenues for each reportable segment. Corporate expenses are not allocated to the segments and are managed at a consolidated level. The CODM does not use total assets by segment to evaluate segment performance or allocate resources, and accordingly, these amounts are not required to be disclosed. The Company's CODM now regularly reviews disaggregated financial information for each of the Company's operating segments. The Company's segment presentation has been recast to retrospectively reflect the change from one reportable segment to the newly identified reportable segments. For the three and six months ended June 30, 2019 , the Company's reportable segments are (i) Precigen, (ii) the Methane Bioconversion Platform division, (iii) the Fine Chemicals division, (iv) Okanagan, and (v) Trans Ova. These identified reportable segments met the quantitative thresholds for the six months ended June 30, 2019 , to be reported separately. See Note 1 for a description of Precigen, Okanagan, and Trans Ova. The Company's Methane Bioconversion Platform division is an operating division within Intrexon which is focused primarily on the development of microbial cell lines for the bioconversion of methane into liquid fuels and chemicals. The Company's Fine Chemicals division is an operating division within Intrexon which is focused primarily on microbial production of therapeutic compounds. The All Other category as reported below reflects Intrexon's consolidated subsidiaries and operating divisions that do not meet the quantitative thresholds to report separately. Information by reportable segment was as follows: Three Months Ended June 30, 2019 Precigen Methane Bioconversion Platform Fine Chemicals Okanagan Trans Ova All Other Total Revenues from external customers $ 549 $ 1,215 $ 1,180 $ 19 $ 24,392 $ 8,592 $ 35,947 Intersegment revenues 2,412 2 1,371 — 674 112 4,571 Total revenues $ 2,961 $ 1,217 $ 2,551 $ 19 $ 25,066 $ 8,704 $ 40,518 Segment Adjusted EBITDA $ (7,467 ) $ (9,188 ) $ 855 $ (12,012 ) $ 4,932 $ (10,060 ) $ (32,940 ) Three Months Ended June 30, 2018 Precigen Methane Bioconversion Platform Fine Chemicals Okanagan Trans Ova All Other Total Revenues from external customers $ 7,332 $ 1,371 $ 1,426 $ 20 $ 25,780 $ 9,356 $ 45,285 Intersegment revenues 110 4 1,295 — 77 265 1,751 Total revenues $ 7,442 $ 1,375 $ 2,721 $ 20 $ 25,857 $ 9,621 $ 47,036 Segment Adjusted EBITDA $ (7,858 ) $ (7,629 ) $ 901 $ (6,280 ) $ 2,096 $ (10,178 ) $ (28,948 ) Six Months Ended June 30, 2019 Precigen Methane Bioconversion Platform Fine Chemicals Okanagan Trans Ova All Other Total Revenues from external customers $ 1,730 $ 2,696 $ 1,990 $ 39 $ 39,326 $ 13,393 $ 59,174 Intersegment revenues 4,777 2 2,865 — 947 568 9,159 Total revenues $ 6,507 $ 2,698 $ 4,855 $ 39 $ 40,273 $ 13,961 $ 68,333 Segment Adjusted EBITDA $ (14,836 ) $ (17,214 ) $ 1,742 $ (21,123 ) $ 2,706 $ (17,494 ) $ (66,219 ) Six Months Ended June 30, 2018 Precigen Methane Bioconversion Platform Fine Chemicals Okanagan Trans Ova All Other Total Revenues from external customers $ 15,463 $ 2,947 $ 3,108 $ 27 $ 43,987 $ 19,464 $ 84,996 Intersegment revenues 231 6 2,794 — 92 720 3,843 Total revenues $ 15,694 $ 2,953 $ 5,902 $ 27 $ 44,079 $ 20,184 $ 88,839 Segment Adjusted EBITDA $ (12,832 ) $ (13,867 ) $ 1,893 $ (11,451 ) $ (57 ) $ (22,034 ) $ (58,348 ) The table below reconciles total revenues from reportable segments to total consolidated revenues: Three Months Ended Six Months Ended 2019 2018 2019 2018 Total revenues from reportable segments $ 31,814 $ 37,415 $ 54,372 $ 68,655 Other revenues, including from other operating segments 8,743 9,726 14,108 20,581 Elimination of intersegment revenues (4,571 ) (1,866 ) (9,159 ) (4,295 ) Total consolidated revenues $ 35,986 $ 45,275 $ 59,321 $ 84,941 The table below reconciles Segment Adjusted EBITDA for reportable segments to consolidated net loss before income taxes: Three Months Ended Six Months Ended 2019 2018 2019 2018 Segment Adjusted EBITDA for reportable segments $ (22,880 ) $ (18,770 ) $ (48,725 ) $ (36,314 ) All Other Segment Adjusted EBITDA (10,060 ) (10,178 ) (17,494 ) (22,034 ) Remove cash paid for capital expenditures and investments in affiliates 14,695 9,668 25,985 20,049 Add recognition of previously deferred revenue associated with upfront and milestone payments 7,262 7,054 10,915 16,899 Other expenses: Interest expense (4,358 ) (142 ) (8,669 ) (241 ) Depreciation and amortization (6,113 ) (8,499 ) (12,690 ) (16,881 ) Stock-based compensation expense (61 ) (8,846 ) (9,115 ) (20,208 ) Equity in net loss of affiliates (1,747 ) (4,550 ) (3,387 ) (7,010 ) Unallocated corporate costs (13,032 ) (33,122 ) (32,978 ) (52,673 ) Eliminations (3,162 ) (571 ) (6,012 ) (1,038 ) Consolidated net loss before income taxes $ (39,456 ) $ (67,956 ) $ (102,170 ) $ (119,451 ) As of June 30, 2019 and December 31, 2018 , the Company had $8,753 and $16,839 , respectively, of long-lived assets in foreign countries. The Company recognized revenues derived in foreign countries totaling $2,195 and $3,951 for the three months ended June 30, 2019 and 2018 , respectively, and $4,460 and $8,154 for the six months ended June 30, 2019 and 2018 , respectively. |
Subsequent Events
Subsequent Events | 6 Months Ended |
Jun. 30, 2019 | |
Subsequent Events [Abstract] | |
Subsequent Events | Subsequent Events On August 8, 2019, the Company entered into an Investment and Contribution Agreement with a third party (the "Investor") related to the Company's MBP technology (the "Investment and Contribution Agreement"). Under the terms of the Investment and Contribution Agreement, in exchange for membership interests in a newly formed limited liability company. Intrexon will contribute assets related to its MBP technology and its interests in Intrexon Energy Partners and Intrexon Energy Partners II, and the Investor will invest $60,000 , $20,000 of which will be invested on each of the closing date, the eight month anniversary of that date, and the sixteen month anniversary of that date. The closing of the Investment and Contribution Agreement, which is subject to closing conditions, is expected to occur during the third calendar quarter of 2019. The Company is still evaluating the accounting impact of the Investment and Contribution Agreement. |
Summary of Significant Accoun_2
Summary of Significant Accounting Policies (Policies) | 6 Months Ended |
Jun. 30, 2019 | |
Accounting Policies [Abstract] | |
Basis of Presentation | Basis of Presentation The accompanying interim consolidated financial statements are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"). Certain information and footnote disclosures normally included in the Company's annual financial statements have been condensed or omitted. These interim consolidated financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for fair statement of the Company's financial position as of June 30, 2019 and results of operations and cash flows for the interim periods ended June 30, 2019 and 2018 . The year-end consolidated balance sheet data was derived from the Company's audited financial statements but does not include all disclosures required by U.S. GAAP. These interim financial results are not necessarily indicative of the results to be expected for the year ending December 31, 2019 , or for any other future annual or interim period. The accompanying interim unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2018 . |
Consolidation | The accompanying consolidated financial statements reflect the operations of the Company and its subsidiaries. All intercompany accounts and transactions have been eliminated. |
Equity Securities | Equity Securities The Company holds equity securities of private and publicly traded companies, including investments received and/or purchased from certain collaborators. The Company elected the fair value option to account for its equity securities held in publicly traded companies. These equity securities are recorded at fair value at each reporting date and are subject to market price volatility. Unrealized gains and losses resulting from fair value adjustments are reported in the consolidated statements of operations. The fair value of these equity securities is subject to fluctuation in the future due to the volatility of the stock market, changes in general economic conditions and changes in the financial conditions of these collaborators. The Company accounts for its investments in private companies using either the equity method, as discussed below, or the measurement alternative method for equity securities without readily determinable fair values, which represents cost and any adjustments for impairment or observable price changes in certain transactions. Equity securities that the Company does not intend to sell within one year are classified as noncurrent in the consolidated balance sheet. For equity securities received pursuant to a collaboration agreement, the Company records the fair value of securities received on the date the collaboration is consummated or the milestone is achieved using the fair value of the collaborator's security on that date, assuming the transfer of consideration is considered perfunctory. If the transfer of the consideration is not considered perfunctory, the Company considers the specific facts and circumstances to determine the appropriate date on which to evaluate fair value. The Company also evaluates whether any discounts for trading restrictions or other basis for lack of marketability should be applied to the fair value of the securities at inception of the collaboration. In the event the Company concludes that a discount should be applied, the fair value of the securities is adjusted at inception of the collaboration and re-evaluated at each reporting period thereafter. |
Equity Method Investments | Equity Method Investments |
Operating Leases | Operating Leases The Company adopted Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Topic 842, Leases ("ASC 842"), effective January 1, 2019. Under ASC 842, the Company determines if an arrangement is a lease at inception. Operating leases are included as right-of-use assets ("ROU Assets") and lease liabilities on the consolidated balance sheets. The Company has elected not to recognize ROU Assets or lease liabilities for leases with lease terms of one year or less. ROU Assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. For leases that contain fixed non-lease payments, the Company accounts for the lease and non-lease components as a single lease component. Variable lease payments, which primarily include payments for non-lease components such as maintenance costs, are excluded from the ROU Assets and lease liabilities and are recognized in the period in which the obligation for those payments is incurred. As most of the Company's operating leases do not provide an implicit interest rate, the Company uses its incremental borrowing rate at the lease commencement date, which is the estimated rate the Company would be required to pay for a collateralized borrowing equal to the total lease payments over the term of the lease, in determining the present value of future payments. The initial measurement of the ROU Asset also includes any lease payments made and excludes lease incentives. The lease term for all of the Company's leases includes the noncancelable period of the lease plus any additional periods covered by options that the Company is reasonably certain to exercise, either to extend or to not terminate the lease. Lease expense is recognized on a straight-line basis over the lease term. |
Use of Estimates | Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. |
Segment Information | Segment Information The Company realigned its business in April 2019, and as a result, its chief operating decision maker ("CODM") now regularly reviews disaggregated financial information for various operating segments. The Company's reportable segments now include (i) Precigen; (ii) the Methane Bioconversion Platform division, which is an operating division of Intrexon; (iii) the Fine Chemicals division, which is also an operating division of Intrexon; (iv) Okanagan; and (v) Trans Ova. All of Intrexon's consolidated subsidiaries and operating divisions that did not meet the quantitative thresholds to report separately are combined and reported in a single category, All Other. See Note 1 for a description of Precigen, Okanagan, and Trans Ova. Corporate expenses are not allocated to the segments and are managed at a consolidated level. The Company's segment presentation has been recast to retrospectively reflect the change from one reportable segment to multiple reportable segments. See Note 19 for further discussion of the Company's segments. |
Recently Issued and Adopted Accounting Pronouncements | Recently Adopted Accounting Pronouncements The Company adopted ASC 842 on January 1, 2019 using the modified retrospective method as of the adoption date without restating prior periods. In addition, the Company elected to use the package of practical expedients which allowed the Company to not have to reassess whether expired or existing contracts contain leases under the new definition of a lease or the lease classification for expired or existing leases under ASC Topic 840. As a result of the adoption of ASC 842, the Company recorded ROU Assets and lease liabilities of approximately $43,500 and $45,500 , respectively, as of January 1, 2019. The difference between the ROU Assets and lease liabilities primarily represents the balance of deferred rent as of December 31, 2018 that resulted from historical straight-lining of operating leases expense, which was reclassified upon adoption to reduce the measurement of the ROU Assets. In June 2018, the FASB issued Accounting Standards Update ("ASU") 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting ("ASU 2018-07"). The provisions of ASU 2018-07 expand the scope of ASC Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. The Company adopted this standard effective January 1, 2019, and there was no material impact to the accompanying consolidated financial statements. Recently Issued Accounting Pronouncements In October 2018, the FASB issued ASU 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606 ("ASU 2018-18"). The provisions of ASU 2018-18 clarify when certain transactions between collaborative arrangement participants should be accounted for under ASC Topic 606, Revenue from Contracts with Customers ("ASC 606"), and incorporates unit-of-account guidance consistent with ASC 606 to aid in this determination. The guidance is effective for annual periods and interim periods within those annual periods beginning after December 15, 2019, with early adoption permitted, and is effective for the Company for the year ending December 31, 2020. The Company is currently evaluating the impact that the implementation of this standard will have on the Company's consolidated financial statements. In October 2018, the FASB issued ASU 2018-17, Consolidation (Topic 810): Targeted Improvements to Related Party Guidance for Variable Interest Entities ("ASU 2018-17"). The provisions of ASU 2018-17 modify the guidance under ASC Topic 810 related to the evaluation of indirect interests held through related parties under common control when determining whether fees paid to decision makers and service providers are variable interests. Indirect interests held through related parties that are under common control are no longer considered to be the equivalent of direct interests in their entirety and instead should be considered on a proportional basis. This guidance more closely aligns with accounting of how indirect interests held through related parties under common control are considered for determining whether a reporting entity must consolidate a VIE. The guidance is effective for annual periods and interim periods within those annual periods beginning after December 15, 2019, with early adoption permitted, and is effective for the Company for the year ending December 31, 2020. The Company is currently evaluating the impact that the implementation of this standard will have on the Company's consolidated financial statements. In August 2018, the FASB issued ASU 2018-15, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract ("ASU 2018-15"). The provisions of ASU 2018-15 clarify the accounting for implementation costs of a hosting arrangement that is a service contract. The new standard requires an entity (customer) in a hosting arrangement that is a service contract to follow existing internal-use software guidance to determine which implementation costs to capitalize as an asset related to the service contract and which costs to expense. Capitalized implementation costs of a hosting arrangement that is a service contract should be amortized over the term of the hosting arrangement, which might extend beyond the noncancelable period if there are options to extend or terminate. ASU 2018-15 also specifies the financial statement presentation of capitalized implementation costs and related amortization, in addition to required disclosures for material capitalized implementation costs related to hosting arrangements that are service contracts. The guidance is effective for annual periods and interim periods within those annual periods beginning after December 15, 2019, with early adoption permitted, and is effective for the Company for the year ending December 31, 2020. The Company is currently evaluating the impact that the implementation of this standard will have on the Company's consolidated financial statements. In August 2018, the FASB issued ASU 2018-13, Fair Value Measurements (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurements ("ASU 2018-13"). The provisions of ASU 2018-13 modify the disclosures related to recurring and nonrecurring fair value measurements. Disclosures related to the transfer of assets between Level 1 and Level 2 hierarchies have been eliminated and various additional disclosures related to Level 3 fair value measurements have been added, modified or removed. The guidance is effective for annual periods and interim periods within those annual periods beginning after December 15, 2019, but entities are permitted to early adopt either the entire standard or only the provisions that eliminate or modify the requirements. This standard is effective for the Company for the year ending December 31, 2020. The Company is currently evaluating the impact that the implementation of this standard will have on the Company's consolidated financial statements. In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments ("ASU 2016-13") . The provisions of ASU 2016-13 modify the impairment model to utilize an expected loss methodology in place of the currently used incurred loss methodology, and requires a consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The guidance is effective for annual periods and interim periods within those annual periods beginning after December 15, 2019, with early adoption permitted, and is effective for the Company for the year ending December 31, 2020. The Company is currently evaluating the impact that the implementation of this standard will have on the Company's consolidated financial statements. In April 2019, the FASB issued ASU 2019-04, Codification Improvements to Topic 326, Financial Instruments-Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments ("ASU 2019-04"). The provisions of ASU 2019-04 clarify and improve areas of guidance related to ASU 2016-13 and ASC Topic 825, Financial Instruments ("ASC 825"). The amendments to ASU 2016-13 have the same effective date as the original ASU and are effective for the Company for the year ending December 31, 2020. The amendments to ASC 825 are effective for fiscal years beginning after December 15, 2019, with early adoption permitted, and are effective for the Company for the year ending December 31, 2020. The Company is currently evaluating the impact that the implementation of this standard will have on the Company's consolidated financial statements. |
Summary of Significant Accoun_3
Summary of Significant Accounting Policies (Tables) | 6 Months Ended |
Jun. 30, 2019 | |
Accounting Policies [Abstract] | |
Summarized Financial Information for the Equity Method Investments | Summarized financial data as of June 30, 2019 and December 31, 2018 and for the three and six months ended June 30, 2019 and 2018 , for the Company's equity method investments are shown in the following tables. June 30, December 31, Current assets $ 22,159 $ 17,485 Noncurrent assets 58,286 31,274 Total assets 80,445 48,759 Current liabilities 7,260 4,226 Noncurrent liabilities 4,872 — Total liabilities 12,132 4,226 Net assets $ 68,313 $ 44,533 Three Months Ended Six Months Ended 2019 2018 2019 2018 Revenues $ 297 $ 173 $ 395 $ 240 Operating expenses 9,384 10,531 14,761 19,141 Operating loss (9,087 ) (10,358 ) (14,366 ) (18,901 ) Other, net 4 7 8 21 Net loss $ (9,083 ) $ (10,351 ) $ (14,358 ) $ (18,880 ) |
Collaboration and Licensing R_2
Collaboration and Licensing Revenue (Tables) | 6 Months Ended |
Jun. 30, 2019 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Summarized Collaboration and Licensing Revenues | The following table summarizes the amounts recorded as revenue in the consolidated statements of operations for each significant counterparty to a collaboration or licensing agreement for the three and six months ended June 30, 2019 and 2018 . Three Months Ended Six Months Ended 2019 2018 2019 2018 ZIOPHARM Oncology, Inc. $ 533 $ 3,423 $ 1,699 $ 8,800 Ares Trading S.A. — 3,526 — 5,949 Oragenics, Inc. 181 37 384 162 Intrexon T1D Partners, LLC — 703 — 2,031 Intrexon Energy Partners, LLC 796 819 1,773 2,016 Intrexon Energy Partners II, LLC 420 553 924 931 Surterra Holdings, Inc. 160 — 160 — Genopaver, LLC 398 1,072 692 2,387 Fibrocell Science, Inc. 2,462 331 2,845 624 Persea Bio, LLC 810 306 (462 ) 515 Harvest start-up entities (1) 2,039 5,904 4,762 9,101 Other 1,298 776 2,290 4,782 Total $ 9,097 $ 17,450 $ 15,067 $ 37,298 (1) For the three and six months ended June 30, 2019 and 2018 , revenues recognized from collaborations with Harvest start-up entities include: Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; and AD Skincare, Inc. For the three and six months ended June 30, 2018 , revenues recognized from collaborations with Harvest start-up entities also include Genten Therapeutics, Inc. and CRS Bio, Inc. |
Summary of Deferred Revenue | Deferred revenue consists of the following: June 30, December 31, Collaboration and licensing agreements $ 78,265 $ 63,284 Prepaid product and service revenues 2,523 2,933 Other 2,347 3,547 Total $ 83,135 $ 69,764 Current portion of deferred revenue $ 16,593 $ 15,554 Long-term portion of deferred revenue 66,542 54,210 Total $ 83,135 $ 69,764 |
Summary of Deferred Revenue by Collaborator | The following table summarizes the remaining balance of deferred revenue associated with upfront and milestone payments for each significant counterparty to a collaboration or licensing agreement as of June 30, 2019 and December 31, 2018 , including the estimated remaining performance period as of June 30, 2019 . Average Remaining Performance Period (Years) June 30, December 31, ZIOPHARM Oncology, Inc. 0.3 $ 398 $ 1,214 Oragenics, Inc. 4.9 5,552 5,810 Intrexon Energy Partners, LLC 4.8 9,059 10,267 Intrexon Energy Partners II, LLC 5.4 13,136 14,060 Surterra Holdings, Inc. 9.0 14,500 — Genopaver, LLC 4.8 1,162 1,175 Fibrocell Science, Inc. 5.4 18,507 17,519 Persea Bio, LLC 5.5 3,839 2,697 Harvest start-up entities (1) 5.7 6,993 7,644 Other 1.8 5,028 2,898 Total $ 78,174 $ 63,284 (1) As of June 30, 2019 and December 31, 2018 , the balance of deferred revenue for collaborations with Harvest start-up entities includes: Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; and AD Skincare, Inc. |
Short-term Investments (Tables)
Short-term Investments (Tables) | 6 Months Ended |
Jun. 30, 2019 | |
Investments, Debt and Equity Securities [Abstract] | |
Summary of Amortized Cost, Gross Unrealized Gains and Losses, and Fair Value of Short-term Investments | The following table summarizes the amortized cost, gross unrealized gains and losses, and fair value of available-for-sale investments as of June 30, 2019 : Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Aggregate Fair Value U.S. government debt securities $ 67,256 $ 45 $ — $ 67,301 Certificates of deposit 340 — — 340 Total $ 67,596 $ 45 $ — $ 67,641 The following table summarizes the amortized cost, gross unrealized gains and losses, and fair value of available-for-sale investments as of December 31, 2018 : Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Aggregate Fair Value U.S. government debt securities $ 119,401 $ — $ (61 ) $ 119,340 Certificates of deposit 348 — — 348 Total $ 119,749 $ — $ (61 ) $ 119,688 |
Fair Value Measurements (Tables
Fair Value Measurements (Tables) | 6 Months Ended |
Jun. 30, 2019 | |
Fair Value Disclosures [Abstract] | |
Summary of Placement in the Fair Value Hierarchy of Financial Assets that are Measured at Fair Value on a Recurring Basis | The following table presents the placement in the fair value hierarchy of financial assets that are measured at fair value on a recurring basis, including the items for which the fair value option has been elected, at June 30, 2019 : Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) June 30, Assets U.S. government debt securities $ — $ 67,301 $ — $ 67,301 Equity securities 1,196 266 20,041 21,503 Other — 468 247 715 Total $ 1,196 $ 68,035 $ 20,288 $ 89,519 The following table presents the placement in the fair value hierarchy of financial assets that are measured at fair value on a recurring basis, including the items for which the fair value option has been elected, at December 31, 2018 : Quoted Prices in Active Markets Significant Other Observable Inputs Significant Unobservable Inputs December 31, Assets U.S. government debt securities $ — $ 119,340 $ — $ 119,340 Equity securities 1,626 556 — 2,182 Other — 468 191 659 Total $ 1,626 $ 120,364 $ 191 $ 122,181 |
Schedule of Changes in Level 3 Investments | The following table summarizes the changes in the Level 3 investments in equity securities and preferred stock during the six months ended June 30, 2019 . Six Months Ended Beginning balance $ 191 Retained interest in deconsolidated subsidiary 14,239 Dividend income from investments in preferred stock 25 Net unrealized appreciation in the fair value of the investments in equity securities and preferred stock 5,833 Ending balance $ 20,288 |
Inventory (Tables)
Inventory (Tables) | 6 Months Ended |
Jun. 30, 2019 | |
Inventory Disclosure [Abstract] | |
Schedule of Inventory | Inventory consists of the following: June 30, December 31, Supplies, embryos and other production materials $ 2,962 $ 4,729 Work in process 4,893 4,391 Livestock 9,462 10,167 Feed 875 2,160 Total inventory $ 18,192 $ 21,447 |
Property, Plant and Equipment_2
Property, Plant and Equipment, Net (Tables) | 6 Months Ended |
Jun. 30, 2019 | |
Property, Plant and Equipment [Abstract] | |
Schedule of Property, Plant and Equipment | Property, plant and equipment consist of the following: June 30, December 31, Land and land improvements $ 11,674 $ 12,490 Buildings and building improvements 11,590 20,371 Furniture and fixtures 1,684 1,891 Equipment 68,138 74,555 Leasehold improvements 31,925 28,289 Breeding stock 4,675 4,582 Computer hardware and software 12,131 11,697 Trees 16,141 11,910 Construction and other assets in progress 23,000 18,880 180,958 184,665 Less: Accumulated depreciation and amortization (60,557 ) (55,791 ) Property, plant and equipment, net $ 120,401 $ 128,874 |
Goodwill and Intangible Asset_2
Goodwill and Intangible Assets, Net (Tables) | 6 Months Ended |
Jun. 30, 2019 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Schedule of Changes in Carrying Amount of Goodwill | The changes in the carrying amount of goodwill for the six months ended June 30, 2019 are as follows: Balance at December 31, 2018 $ 149,585 Foreign currency translation adjustments 331 Balance at June 30, 2019 $ 149,916 |
Schedule of Intangible Assets | Intangible assets consist of the following as of June 30, 2019 : Gross Carrying Amount Accumulated Amortization Net Patents, developed technologies and know-how $ 139,363 $ (37,251 ) $ 102,112 Customer relationships 10,700 (8,002 ) 2,698 Trademarks 5,900 (3,514 ) 2,386 In-process research and development 5,330 — 5,330 Total $ 161,293 $ (48,767 ) $ 112,526 Intangible assets consist of the following as of December 31, 2018 : Gross Carrying Amount Accumulated Amortization Net Patents, developed technologies and know-how $ 152,482 $ (35,133 ) $ 117,349 Customer relationships 10,700 (7,565 ) 3,135 Trademarks 6,800 (3,341 ) 3,459 In-process research and development 5,348 — 5,348 Total $ 175,330 $ (46,039 ) $ 129,291 |
Lines of Credit and Long-Term_2
Lines of Credit and Long-Term Debt (Tables) | 6 Months Ended |
Jun. 30, 2019 | |
Debt Disclosure [Abstract] | |
Schedule of Long-Term Debt Instruments | Long-term debt consists of the following: June 30, December 31, Convertible debt $ 208,376 $ 203,391 Notes payable 4,320 4,551 Other 251 3,852 Long-term debt 212,947 211,794 Less current portion 468 559 Long-term debt, less current portion $ 212,479 $ 211,235 |
Schedule of Future Maturities of Long-Term Debt | Future maturities of long-term debt are as follows: 2019 $ 241 2020 31,254 2021 25,329 2022 339 2023 200,353 2024 366 Thereafter 2,431 Total $ 260,313 |
Shareholders' Equity (Tables)
Shareholders' Equity (Tables) | 6 Months Ended |
Jun. 30, 2019 | |
Equity [Abstract] | |
Components of Accumulated Other Comprehensive Loss | The components of accumulated other comprehensive loss are as follows: June 30, December 31, Unrealized gain (loss) on investments $ 45 $ (61 ) Loss on foreign currency translation adjustments (28,251 ) (28,551 ) Total accumulated other comprehensive loss $ (28,206 ) $ (28,612 ) |
Share-Based Payments (Tables)
Share-Based Payments (Tables) | 6 Months Ended |
Jun. 30, 2019 | |
Share-based Payment Arrangement [Abstract] | |
Schedule of Stock-Based Compensation Costs | Stock-based compensation costs included in the consolidated statements of operations are presented below: Three Months Ended Six Months Ended 2019 2018 2019 2018 Cost of products $ 4 $ 25 $ 12 $ 50 Cost of services 52 79 117 156 Research and development 1,882 2,376 3,727 5,634 Selling, general and administrative (1,877 ) 6,366 5,259 14,368 Total $ 61 $ 8,846 $ 9,115 $ 20,208 |
Schedule of Stock Option Activity | Stock option activity was as follows: Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Balances at December 31, 2018 11,093,063 $ 27.95 6.81 Granted 1,433,075 6.46 Exercised (17,811 ) (3.17 ) Forfeited (634,204 ) (35.36 ) Expired (143,169 ) (28.38 ) Balances at June 30, 2019 11,730,954 24.96 5.75 Exercisable at June 30, 2019 8,179,447 28.82 4.52 |
Schedule of Restricted Stock Unit Activity | RSU activity was as follows: Number of Restricted Stock Units Weighted Average Grant Date Fair Value Weighted Average Remaining Contractual Term (Years) Balances at December 31, 2018 970,341 $ 13.82 1.43 Granted 2,278,460 6.59 Vested (765,112 ) (9.75 ) Forfeited (212,412 ) (9.20 ) Balances at June 30, 2019 2,271,277 8.37 1.49 |
Operating Leases (Tables)
Operating Leases (Tables) | 6 Months Ended |
Jun. 30, 2019 | |
Leases [Abstract] | |
Components of Lease Costs | June 30, Weighted average remaining lease term (years) 8.98 Weighted average discount rate 11.35 % Other information related to operating leases was as follows: Six Months Ended 2019 Supplemental Cash Flows Information Cash paid for operating lease liabilities $ 4,929 Operating lease right-of-use assets added in exchange for new lease liabilities 1,125 The components of lease costs were as follows: Three Months Ended Six Months Ended 2019 2019 Operating lease costs $ 2,522 $ 5,048 Short-term and variable lease costs 1,120 2,168 Lease costs $ 3,642 $ 7,216 |
Maturities of Lease Liabilities | Maturities of lease liabilities as of June 30, 2019 were as follows: 2019 $ 4,352 2020 10,088 2021 9,445 2022 8,646 2023 7,274 2024 7,139 Thereafter 26,746 Total 73,690 Present value adjustment (30,120 ) Total $ 43,570 Current portion of operating lease liabilities $ 4,813 Long-term portion of operating lease liabilities 38,757 Total $ 43,570 |
Future Minimum Lease Payments | At December 31, 2018 , future minimum lease payments under operating leases having initial or remaining noncancelable lease terms in excess of one year were as follows: 2019 $ 9,182 2020 9,910 2021 9,127 2022 8,305 2023 7,229 Thereafter 34,157 Total $ 77,910 |
Net Loss per Share (Tables)
Net Loss per Share (Tables) | 6 Months Ended |
Jun. 30, 2019 | |
Earnings Per Share [Abstract] | |
Computation of Basic and Diluted Net Loss per Share | The following table presents the computation of basic and diluted net loss per share: Three Months Ended Six Months Ended 2019 2018 2019 2018 Historical net loss per share: Numerator: Net loss attributable to Intrexon $ (38,766 ) $ (65,382 ) $ (99,475 ) $ (111,547 ) Denominator: Weighted average shares outstanding, basic and diluted 153,749,929 129,299,584 153,351,208 128,500,897 Net loss attributable to Intrexon per share, basic and diluted $ (0.25 ) $ (0.51 ) $ (0.65 ) $ (0.87 ) |
Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Share | The following potentially dilutive securities as of June 30, 2019 and 2018 , have been excluded from the above computations of diluted weighted average shares outstanding for the three and six months then ended as they would have been anti-dilutive: June 30, 2019 2018 Convertible debt 19,667,765 — Options 11,730,954 11,359,531 Restricted stock units 2,271,277 1,033,084 Warrants 133,264 133,264 Total 33,803,260 12,525,879 |
Segments (Tables)
Segments (Tables) | 6 Months Ended |
Jun. 30, 2019 | |
Segment Reporting [Abstract] | |
Information by Reportable Segment | Information by reportable segment was as follows: Three Months Ended June 30, 2019 Precigen Methane Bioconversion Platform Fine Chemicals Okanagan Trans Ova All Other Total Revenues from external customers $ 549 $ 1,215 $ 1,180 $ 19 $ 24,392 $ 8,592 $ 35,947 Intersegment revenues 2,412 2 1,371 — 674 112 4,571 Total revenues $ 2,961 $ 1,217 $ 2,551 $ 19 $ 25,066 $ 8,704 $ 40,518 Segment Adjusted EBITDA $ (7,467 ) $ (9,188 ) $ 855 $ (12,012 ) $ 4,932 $ (10,060 ) $ (32,940 ) Three Months Ended June 30, 2018 Precigen Methane Bioconversion Platform Fine Chemicals Okanagan Trans Ova All Other Total Revenues from external customers $ 7,332 $ 1,371 $ 1,426 $ 20 $ 25,780 $ 9,356 $ 45,285 Intersegment revenues 110 4 1,295 — 77 265 1,751 Total revenues $ 7,442 $ 1,375 $ 2,721 $ 20 $ 25,857 $ 9,621 $ 47,036 Segment Adjusted EBITDA $ (7,858 ) $ (7,629 ) $ 901 $ (6,280 ) $ 2,096 $ (10,178 ) $ (28,948 ) Six Months Ended June 30, 2019 Precigen Methane Bioconversion Platform Fine Chemicals Okanagan Trans Ova All Other Total Revenues from external customers $ 1,730 $ 2,696 $ 1,990 $ 39 $ 39,326 $ 13,393 $ 59,174 Intersegment revenues 4,777 2 2,865 — 947 568 9,159 Total revenues $ 6,507 $ 2,698 $ 4,855 $ 39 $ 40,273 $ 13,961 $ 68,333 Segment Adjusted EBITDA $ (14,836 ) $ (17,214 ) $ 1,742 $ (21,123 ) $ 2,706 $ (17,494 ) $ (66,219 ) Six Months Ended June 30, 2018 Precigen Methane Bioconversion Platform Fine Chemicals Okanagan Trans Ova All Other Total Revenues from external customers $ 15,463 $ 2,947 $ 3,108 $ 27 $ 43,987 $ 19,464 $ 84,996 Intersegment revenues 231 6 2,794 — 92 720 3,843 Total revenues $ 15,694 $ 2,953 $ 5,902 $ 27 $ 44,079 $ 20,184 $ 88,839 Segment Adjusted EBITDA $ (12,832 ) $ (13,867 ) $ 1,893 $ (11,451 ) $ (57 ) $ (22,034 ) $ (58,348 ) |
Reconciliation of Operating Profit (Loss) from Segments to Consolidated | The table below reconciles total revenues from reportable segments to total consolidated revenues: Three Months Ended Six Months Ended 2019 2018 2019 2018 Total revenues from reportable segments $ 31,814 $ 37,415 $ 54,372 $ 68,655 Other revenues, including from other operating segments 8,743 9,726 14,108 20,581 Elimination of intersegment revenues (4,571 ) (1,866 ) (9,159 ) (4,295 ) Total consolidated revenues $ 35,986 $ 45,275 $ 59,321 $ 84,941 The table below reconciles Segment Adjusted EBITDA for reportable segments to consolidated net loss before income taxes: Three Months Ended Six Months Ended 2019 2018 2019 2018 Segment Adjusted EBITDA for reportable segments $ (22,880 ) $ (18,770 ) $ (48,725 ) $ (36,314 ) All Other Segment Adjusted EBITDA (10,060 ) (10,178 ) (17,494 ) (22,034 ) Remove cash paid for capital expenditures and investments in affiliates 14,695 9,668 25,985 20,049 Add recognition of previously deferred revenue associated with upfront and milestone payments 7,262 7,054 10,915 16,899 Other expenses: Interest expense (4,358 ) (142 ) (8,669 ) (241 ) Depreciation and amortization (6,113 ) (8,499 ) (12,690 ) (16,881 ) Stock-based compensation expense (61 ) (8,846 ) (9,115 ) (20,208 ) Equity in net loss of affiliates (1,747 ) (4,550 ) (3,387 ) (7,010 ) Unallocated corporate costs (13,032 ) (33,122 ) (32,978 ) (52,673 ) Eliminations (3,162 ) (571 ) (6,012 ) (1,038 ) Consolidated net loss before income taxes $ (39,456 ) $ (67,956 ) $ (102,170 ) $ (119,451 ) |
Organization (Details)
Organization (Details) $ in Thousands | 3 Months Ended | 6 Months Ended |
Jun. 30, 2019USD ($) | Jun. 30, 2019USD ($) | |
Noncontrolling Interest [Line Items] | ||
Loss on deconsolidation of subsidiary | $ 2,648 | $ 2,648 |
Net assets divested from deconsolidation | $ 38,682 | $ 38,682 |
AquaBounty Technologies, Inc. | ||
Noncontrolling Interest [Line Items] | ||
Ownership interest | 38.00% | 38.00% |
Summary of Significant Accoun_4
Summary of Significant Accounting Policies - Liquidity and Going Concern - Additional Information (Details) $ in Thousands | Jun. 30, 2019USD ($) |
Accounting Policies [Abstract] | |
Cash, cash equivalents, and short-term investments | $ 125,803 |
Summary of Significant Accoun_5
Summary of Significant Accounting Policies - Equity Method Investments - Additional Information (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2019 | Jun. 30, 2018 | Jun. 30, 2019 | Jun. 30, 2018 | |
AquaBounty Technologies, Inc. | ||||
Schedule of Equity Method Investments [Line Items] | ||||
Equity method investments, fair value disclosure | $ 20,041 | $ 20,041 | ||
Ownership interest | 38.00% | 38.00% | ||
Unrealized appreciation (depreciation) in fair value of equity securities | $ 5,802 | $ 5,802 | ||
Oragenics, Inc. | ||||
Schedule of Equity Method Investments [Line Items] | ||||
Unrealized appreciation (depreciation) in fair value of equity securities | $ (409) | $ (1,160) |
Summary of Significant Accoun_6
Summary of Significant Accounting Policies - Summarized Financial Information for the Equity Method Investments (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | |||
Jun. 30, 2019 | Jun. 30, 2018 | Jun. 30, 2019 | Jun. 30, 2018 | Dec. 31, 2018 | |
Schedule of Equity Method Investments [Line Items] | |||||
Operating expenses | $ 73,395 | $ 95,010 | $ 155,433 | $ 187,198 | |
Operating loss | (37,409) | (49,735) | (96,112) | (102,257) | |
Other, net | (300) | (13,671) | (2,671) | (10,184) | |
Equity Method Investments | |||||
Schedule of Equity Method Investments [Line Items] | |||||
Current assets | 22,159 | 22,159 | $ 17,485 | ||
Noncurrent assets | 58,286 | 58,286 | 31,274 | ||
Total assets | 80,445 | 80,445 | 48,759 | ||
Current liabilities | 7,260 | 7,260 | 4,226 | ||
Noncurrent liabilities | 4,872 | 4,872 | 0 | ||
Total liabilities | 12,132 | 12,132 | 4,226 | ||
Net assets | 68,313 | 68,313 | $ 44,533 | ||
Revenues | 297 | 173 | 395 | 240 | |
Operating expenses | 9,384 | 10,531 | 14,761 | 19,141 | |
Operating loss | (9,087) | (10,358) | (14,366) | (18,901) | |
Other, net | 4 | 7 | 8 | 21 | |
Net loss | $ (9,083) | $ (10,351) | $ (14,358) | $ (18,880) |
Summary of Significant Accoun_7
Summary of Significant Accounting Policies - Variable Interest Entities - Additional Information (Details) - USD ($) $ in Thousands | Jun. 30, 2019 | Dec. 31, 2018 |
Accounting Policies [Abstract] | ||
Maximum risk of loss related to the identified VIEs | $ 20,238 | $ 21,219 |
Summary of Significant Accoun_8
Summary of Significant Accounting Policies - Recently Issued and Adopted Accounting Pronouncements - Additional Information (Details) - USD ($) $ in Thousands | Jun. 30, 2019 | Jan. 01, 2019 | Dec. 31, 2018 |
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | |||
Right-of-use assets | $ 41,558 | $ 0 | |
Operating lease liabilities | $ 43,570 | ||
Accounting Standards Update 2016-02 | |||
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | |||
Right-of-use assets | $ 43,500 | ||
Operating lease liabilities | $ 45,500 |
Mergers and Acquisitions - Asse
Mergers and Acquisitions - Asset Acquisition of Certain Harvest Entities - Additional Information (Details) - USD ($) | 1 Months Ended | |||
Sep. 30, 2018 | Jun. 30, 2019 | Dec. 31, 2018 | Aug. 31, 2018 | |
Business Acquisition [Line Items] | ||||
Investments in affiliates | $ 18,093,000 | $ 18,859,000 | ||
Deferred revenue | $ 83,135,000 | $ 69,764,000 | ||
Harvest Intrexon Enterprise Fund I, LP | ||||
Business Acquisition [Line Items] | ||||
Cash received in asset acquisition | $ 15,500,000 | |||
Harvest Intrexon Enterprise Fund I, LP | ActoBio Therapeutics Inc. | ||||
Business Acquisition [Line Items] | ||||
Long-term debt issued to a related party in an asset acquisition | 30,000,000 | |||
CRS Bio, Inc.; Genten Therapeutics, Inc.; and Relive Genetics, Inc. | ||||
Business Acquisition [Line Items] | ||||
Investments in affiliates | $ 4,303,000 | |||
Ownership interest | 100.00% | |||
Deferred revenue | 10,078,000 | |||
Write-off of in-process research and development acquired in asset acquisition | $ 8,721,000 |
Investments in Joint Ventures -
Investments in Joint Ventures - Intrexon Energy Partners - Additional Information (Details) | 1 Months Ended | ||
Mar. 31, 2014USD ($) | Jun. 30, 2019USD ($)board_seat | Dec. 31, 2018USD ($) | |
Schedule of Equity Method Investments [Line Items] | |||
Investment | $ 18,093,000 | $ 18,859,000 | |
Intrexon Energy Partners, LLC | |||
Schedule of Equity Method Investments [Line Items] | |||
Ownership interest | 50.00% | ||
Maximum additional capital contribution committed | $ 25,000,000 | ||
Additional capital contributions committed, remaining commitment | $ 4,568,000 | ||
Total number of seats on the joint venture's governing board | board_seat | 5 | ||
Total number of seats on the joint venture's governing board, internally selected | board_seat | 2 | ||
Total number of seats on the joint venture's governing board, externally selected | board_seat | 3 | ||
Intrexon Energy Partners, LLC | Other Accrued Liabilities | |||
Schedule of Equity Method Investments [Line Items] | |||
Investment | $ (585,000) | $ (656,000) | |
Intrexon Energy Partners, LLC | Investors | |||
Schedule of Equity Method Investments [Line Items] | |||
Ownership interest | 50.00% | ||
Capital contributions | $ 25,000,000 | ||
Maximum additional capital contribution committed | 25,000,000 | ||
Intrexon Energy Partners, LLC | Collaboration and licensing agreements | |||
Schedule of Equity Method Investments [Line Items] | |||
Collaborative arrangement consideration received, value | $ 25,000,000 |
Investments in Joint Ventures_2
Investments in Joint Ventures - Intrexon Energy Partners II - Additional Information (Details) | 1 Months Ended | ||
Dec. 31, 2015USD ($)board_seat | Jun. 30, 2019USD ($) | Dec. 31, 2018USD ($) | |
Schedule of Equity Method Investments [Line Items] | |||
Investment | $ 18,093,000 | $ 18,859,000 | |
Intrexon Energy Partners II, LLC | |||
Schedule of Equity Method Investments [Line Items] | |||
Ownership interest | 50.00% | ||
Maximum additional capital contribution committed | $ 10,000,000 | ||
Total number of seats on the joint venture's governing board | board_seat | 5 | ||
Total number of seats on the joint venture's governing board, internally selected | board_seat | 1 | ||
Total number of seats on the joint venture's governing board, externally selected | board_seat | 4 | ||
Intrexon Energy Partners II, LLC | Other Accrued Liabilities | |||
Schedule of Equity Method Investments [Line Items] | |||
Investment | $ (373,000) | $ (50,000) | |
Intrexon Energy Partners II, LLC | Investors | |||
Schedule of Equity Method Investments [Line Items] | |||
Ownership interest | 50.00% | ||
Capital contributions | $ 18,000,000 | ||
Maximum additional capital contribution committed | 10,000,000 | ||
Intrexon Energy Partners II, LLC | All Investors | |||
Schedule of Equity Method Investments [Line Items] | |||
Capital contributions | 4,000,000 | ||
Intrexon Energy Partners II, LLC | Collaboration and licensing agreements | |||
Schedule of Equity Method Investments [Line Items] | |||
Collaborative arrangement consideration received, value | $ 18,000,000 |
Investments in Joint Ventures_3
Investments in Joint Ventures - EnviroFlight - Additional Information (Details) - USD ($) $ in Thousands | 40 Months Ended | |
Jun. 30, 2019 | Dec. 31, 2018 | |
Schedule of Equity Method Investments [Line Items] | ||
Investment | $ 18,093 | $ 18,859 |
EnviroFlight, LLC | ||
Schedule of Equity Method Investments [Line Items] | ||
Capital contributions | 18,000 | |
EnviroFlight, LLC | Investments In Affiliates | ||
Schedule of Equity Method Investments [Line Items] | ||
Investment | 15,798 | $ 16,720 |
Investors | EnviroFlight, LLC | ||
Schedule of Equity Method Investments [Line Items] | ||
Capital contributions | $ 18,000 |
Investments in Joint Ventures_4
Investments in Joint Ventures - Intrexon T1D Partners - Additional Information (Details) | 1 Months Ended | |||
Nov. 30, 2018USD ($)shares | Mar. 31, 2016USD ($) | Jun. 30, 2019USD ($)board_seat | Dec. 31, 2018USD ($) | |
Schedule of Equity Method Investments [Line Items] | ||||
Deferred revenue | $ 83,135,000 | $ 69,764,000 | ||
Collaboration and licensing agreements | ||||
Schedule of Equity Method Investments [Line Items] | ||||
Deferred revenue | $ 78,265,000 | $ 63,284,000 | ||
Intrexon T1D Partners, LLC | ||||
Schedule of Equity Method Investments [Line Items] | ||||
Ownership interest | 100.00% | 50.00% | ||
Maximum additional capital contribution committed | $ 5,000,000 | |||
Total number of seats on the joint venture's governing board, internally selected | board_seat | 2 | |||
Total number of seats on the joint venture's governing board, externally selected | board_seat | 3 | |||
Stock issued during period, shares, purchase of assets (in shares) | shares | 1,933,737 | |||
Stock issued during period, value, purchase of assets | $ 18,970,000 | |||
Deferred revenue | 8,517,000 | |||
Write-off of in-process research and development acquired in asset acquisition | $ 10,453,000 | |||
Intrexon T1D Partners, LLC | Investors | ||||
Schedule of Equity Method Investments [Line Items] | ||||
Ownership interest | 50.00% | |||
Capital contributions | $ 10,000,000 | |||
Maximum additional capital contribution committed | 5,000,000 | |||
Intrexon T1D Partners, LLC | Collaboration and licensing agreements | ||||
Schedule of Equity Method Investments [Line Items] | ||||
Collaborative arrangement consideration received, value | $ 10,000,000 |
Collaboration and Licensing R_3
Collaboration and Licensing Revenue - Summarized Collaboration and Licensing Revenues (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | |||
Jun. 30, 2019 | Jun. 30, 2018 | Jun. 30, 2019 | Jun. 30, 2018 | ||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||
Revenues | $ 35,986 | $ 45,275 | $ 59,321 | $ 84,941 | |
Collaboration and licensing agreements | |||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||
Revenues | 9,097 | 17,450 | 15,067 | 37,298 | |
ZIOPHARM Oncology, Inc. | Collaboration and licensing agreements | |||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||
Revenues | 533 | 3,423 | 1,699 | 8,800 | |
Ares Trading S.A. | Collaboration and licensing agreements | |||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||
Revenues | 0 | 3,526 | 0 | 5,949 | |
Oragenics, Inc. | Collaboration and licensing agreements | |||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||
Revenues | 181 | 37 | 384 | 162 | |
Intrexon T1D Partners, LLC | Collaboration and licensing agreements | |||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||
Revenues | 0 | 703 | 0 | 2,031 | |
Intrexon Energy Partners, LLC | Collaboration and licensing agreements | |||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||
Revenues | 796 | 819 | 1,773 | 2,016 | |
Intrexon Energy Partners II, LLC | Collaboration and licensing agreements | |||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||
Revenues | 420 | 553 | 924 | 931 | |
Surterra Holdings, Inc. | Collaboration and licensing agreements | |||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||
Revenues | 160 | 0 | 160 | 0 | |
Genopaver, LLC | Collaboration and licensing agreements | |||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||
Revenues | 398 | 1,072 | 692 | 2,387 | |
Fibrocell Science, Inc. | Collaboration and licensing agreements | |||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||
Revenues | 2,462 | 331 | 2,845 | 624 | |
Persea Bio, LLC | Collaboration and licensing agreements | |||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||
Revenues | 810 | 306 | (462) | 515 | |
Harvest start-up entities | Collaboration and licensing agreements | |||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||
Revenues | [1] | 2,039 | 5,904 | 4,762 | 9,101 |
Other | Collaboration and licensing agreements | |||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||
Revenues | $ 1,298 | $ 776 | $ 2,290 | $ 4,782 | |
[1] | For the three and six months ended June 30, 2019 and 2018 , revenues recognized from collaborations with Harvest start-up entities include: Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; and AD Skincare, Inc. For the three and six months ended June 30, 2018 , revenues recognized from collaborations with Harvest start-up entities also include Genten Therapeutics, Inc. and CRS Bio, Inc. |
Collaboration and Licensing R_4
Collaboration and Licensing Revenue - Surterra Collaboration (Details) - Surterra Holdings, Inc. $ in Thousands | 1 Months Ended |
Jun. 30, 2019USD ($) | |
Collaboration and licensing agreements | |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |
Collaborative arrangement consideration received, cash | $ 10,000 |
Collaborative arrangement consideration received, value | $ 4,530 |
Collaboration agreement termination notice period | 90 days |
Maximum | |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |
Milestone payments required upon successful achievement | $ 68,000 |
Collaboration and Licensing R_5
Collaboration and Licensing Revenue - Fibrocell Science Collaboration (Details) - Fibrocell Science, Inc. - USD ($) $ in Thousands | 1 Months Ended | |
Apr. 30, 2019 | Jun. 30, 2019 | |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||
Collaboration agreement, percentage of sublicensing income | 50.00% | |
Accounts receivable, related parties | $ 3,750 |
Collaboration and Licensing R_6
Collaboration and Licensing Revenue - Summary of Deferred Revenue (Details) - USD ($) $ in Thousands | Jun. 30, 2019 | Dec. 31, 2018 |
Contract With Customer, Asset And Liability [Line Items] | ||
Deferred revenue | $ 83,135 | $ 69,764 |
Current portion of deferred revenue | 16,593 | 15,554 |
Long-term portion of deferred revenue | 66,542 | 54,210 |
Collaboration and licensing agreements | ||
Contract With Customer, Asset And Liability [Line Items] | ||
Deferred revenue | 78,265 | 63,284 |
Prepaid product and service revenues | ||
Contract With Customer, Asset And Liability [Line Items] | ||
Deferred revenue | 2,523 | 2,933 |
Other | ||
Contract With Customer, Asset And Liability [Line Items] | ||
Deferred revenue | $ 2,347 | $ 3,547 |
Collaboration and Licensing R_7
Collaboration and Licensing Revenue - Summary of Deferred Revenue by Collaborator, Current Year (Details) - USD ($) $ in Thousands | Jun. 30, 2019 | Dec. 31, 2018 | |
Upfront and Milestone Payments | |||
Contract With Customer, Asset And Liability [Line Items] | |||
Deferred revenue | $ 63,284 | ||
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-07-01 | Upfront and Milestone Payments | |||
Contract With Customer, Asset And Liability [Line Items] | |||
Deferred revenue | $ 78,174 | ||
ZIOPHARM Oncology, Inc. | Upfront and Milestone Payments | |||
Contract With Customer, Asset And Liability [Line Items] | |||
Deferred revenue | 1,214 | ||
ZIOPHARM Oncology, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-07-01 | |||
Contract With Customer, Asset And Liability [Line Items] | |||
Average remaining performance period (in years) | 9 days | ||
ZIOPHARM Oncology, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-07-01 | Upfront and Milestone Payments | |||
Contract With Customer, Asset And Liability [Line Items] | |||
Deferred revenue | $ 398 | ||
Oragenics, Inc. | Upfront and Milestone Payments | |||
Contract With Customer, Asset And Liability [Line Items] | |||
Deferred revenue | 5,810 | ||
Oragenics, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-07-01 | |||
Contract With Customer, Asset And Liability [Line Items] | |||
Average remaining performance period (in years) | 4 years 10 months 24 days | ||
Oragenics, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-07-01 | Upfront and Milestone Payments | |||
Contract With Customer, Asset And Liability [Line Items] | |||
Deferred revenue | $ 5,552 | ||
Intrexon Energy Partners, LLC | Upfront and Milestone Payments | |||
Contract With Customer, Asset And Liability [Line Items] | |||
Deferred revenue | 10,267 | ||
Intrexon Energy Partners, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-07-01 | |||
Contract With Customer, Asset And Liability [Line Items] | |||
Average remaining performance period (in years) | 4 years 9 months 18 days | ||
Intrexon Energy Partners, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-07-01 | Upfront and Milestone Payments | |||
Contract With Customer, Asset And Liability [Line Items] | |||
Deferred revenue | $ 9,059 | ||
Intrexon Energy Partners II, LLC | Upfront and Milestone Payments | |||
Contract With Customer, Asset And Liability [Line Items] | |||
Deferred revenue | 14,060 | ||
Intrexon Energy Partners II, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-07-01 | |||
Contract With Customer, Asset And Liability [Line Items] | |||
Average remaining performance period (in years) | 5 years 4 months 24 days | ||
Intrexon Energy Partners II, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-07-01 | Upfront and Milestone Payments | |||
Contract With Customer, Asset And Liability [Line Items] | |||
Deferred revenue | $ 13,136 | ||
Surterra Holdings, Inc. | Upfront and Milestone Payments | |||
Contract With Customer, Asset And Liability [Line Items] | |||
Deferred revenue | 0 | ||
Surterra Holdings, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-07-01 | |||
Contract With Customer, Asset And Liability [Line Items] | |||
Average remaining performance period (in years) | 9 years | ||
Surterra Holdings, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-07-01 | Upfront and Milestone Payments | |||
Contract With Customer, Asset And Liability [Line Items] | |||
Deferred revenue | $ 14,500 | ||
Genopaver, LLC | Upfront and Milestone Payments | |||
Contract With Customer, Asset And Liability [Line Items] | |||
Deferred revenue | 1,175 | ||
Genopaver, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-07-01 | |||
Contract With Customer, Asset And Liability [Line Items] | |||
Average remaining performance period (in years) | 4 years 9 months 18 days | ||
Genopaver, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-07-01 | Upfront and Milestone Payments | |||
Contract With Customer, Asset And Liability [Line Items] | |||
Deferred revenue | $ 1,162 | ||
Fibrocell Science, Inc. | Upfront and Milestone Payments | |||
Contract With Customer, Asset And Liability [Line Items] | |||
Deferred revenue | 17,519 | ||
Fibrocell Science, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-07-01 | |||
Contract With Customer, Asset And Liability [Line Items] | |||
Average remaining performance period (in years) | 5 years 4 months 24 days | ||
Fibrocell Science, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-07-01 | Upfront and Milestone Payments | |||
Contract With Customer, Asset And Liability [Line Items] | |||
Deferred revenue | $ 18,507 | ||
Persea Bio, LLC | Upfront and Milestone Payments | |||
Contract With Customer, Asset And Liability [Line Items] | |||
Deferred revenue | 2,697 | ||
Persea Bio, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-07-01 | |||
Contract With Customer, Asset And Liability [Line Items] | |||
Average remaining performance period (in years) | 5 years 6 months | ||
Persea Bio, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-07-01 | Upfront and Milestone Payments | |||
Contract With Customer, Asset And Liability [Line Items] | |||
Deferred revenue | $ 3,839 | ||
Harvest start-up entities | Upfront and Milestone Payments | |||
Contract With Customer, Asset And Liability [Line Items] | |||
Deferred revenue | [1] | 7,644 | |
Harvest start-up entities | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-07-01 | |||
Contract With Customer, Asset And Liability [Line Items] | |||
Average remaining performance period (in years) | [1] | 5 years 8 months 12 days | |
Harvest start-up entities | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-07-01 | Upfront and Milestone Payments | |||
Contract With Customer, Asset And Liability [Line Items] | |||
Deferred revenue | [1] | $ 6,993 | |
Other | Upfront and Milestone Payments | |||
Contract With Customer, Asset And Liability [Line Items] | |||
Deferred revenue | $ 2,898 | ||
Other | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-07-01 | |||
Contract With Customer, Asset And Liability [Line Items] | |||
Average remaining performance period (in years) | 1 year 9 months 18 days | ||
Other | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-07-01 | Upfront and Milestone Payments | |||
Contract With Customer, Asset And Liability [Line Items] | |||
Deferred revenue | $ 5,028 | ||
[1] | As of June 30, 2019 and December 31, 2018 , the balance of deferred revenue for collaborations with Harvest start-up entities includes: Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; and AD Skincare, Inc. |
Collaboration and Licensing R_8
Collaboration and Licensing Revenue - Summary of Deferred Revenue by Collaborator, Prior Year (Details) - Upfront and Milestone Payments $ in Thousands | Dec. 31, 2018USD ($) | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | ||
Deferred revenue | $ 63,284 | |
ZIOPHARM Oncology, Inc. | ||
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | ||
Deferred revenue | 1,214 | |
Oragenics, Inc. | ||
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | ||
Deferred revenue | 5,810 | |
Intrexon Energy Partners, LLC | ||
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | ||
Deferred revenue | 10,267 | |
Intrexon Energy Partners II, LLC | ||
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | ||
Deferred revenue | 14,060 | |
Surterra Holdings, Inc. | ||
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | ||
Deferred revenue | 0 | |
Genopaver, LLC | ||
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | ||
Deferred revenue | 1,175 | |
Fibrocell Science, Inc. | ||
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | ||
Deferred revenue | 17,519 | |
Persea Bio, LLC | ||
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | ||
Deferred revenue | 2,697 | |
Harvest start-up entities | ||
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | ||
Deferred revenue | 7,644 | [1] |
Other | ||
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | ||
Deferred revenue | $ 2,898 | |
[1] | As of June 30, 2019 and December 31, 2018 , the balance of deferred revenue for collaborations with Harvest start-up entities includes: Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; and AD Skincare, Inc. |
Short-term Investments - Summar
Short-term Investments - Summary of Amortized Cost, Gross Unrealized Gains and Losses, and Fair Value of Short-term Investments (Details) - USD ($) $ in Thousands | Jun. 30, 2019 | Dec. 31, 2018 |
Debt Securities, Available-for-sale [Line Items] | ||
Amortized Cost | $ 67,596 | $ 119,749 |
Gross Unrealized Gains | 45 | 0 |
Gross Unrealized Losses | 0 | (61) |
Aggregate Fair Value | 67,641 | 119,688 |
U.S. government debt securities | ||
Debt Securities, Available-for-sale [Line Items] | ||
Amortized Cost | 67,256 | 119,401 |
Gross Unrealized Gains | 45 | 0 |
Gross Unrealized Losses | 0 | (61) |
Aggregate Fair Value | 67,301 | 119,340 |
Certificates of deposit | ||
Debt Securities, Available-for-sale [Line Items] | ||
Amortized Cost | 340 | 348 |
Gross Unrealized Gains | 0 | 0 |
Gross Unrealized Losses | 0 | 0 |
Aggregate Fair Value | $ 340 | $ 348 |
Fair Value Measurements - Summa
Fair Value Measurements - Summary of Placement in the Fair Value Hierarchy of Financial Assets that are Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands | Jun. 30, 2019 | Dec. 31, 2018 |
Assets | ||
Fair value of financial assets measured at fair value on a recurring basis | $ 89,519 | $ 122,181 |
Quoted Prices in Active Markets (Level 1) | ||
Assets | ||
Fair value of financial assets measured at fair value on a recurring basis | 1,196 | 1,626 |
Significant Other Observable Inputs (Level 2) | ||
Assets | ||
Fair value of financial assets measured at fair value on a recurring basis | 68,035 | 120,364 |
Significant Unobservable Inputs (Level 3) | ||
Assets | ||
Fair value of financial assets measured at fair value on a recurring basis | 20,288 | 191 |
U.S. government debt securities | ||
Assets | ||
Fair value of financial assets measured at fair value on a recurring basis | 67,301 | 119,340 |
U.S. government debt securities | Quoted Prices in Active Markets (Level 1) | ||
Assets | ||
Fair value of financial assets measured at fair value on a recurring basis | 0 | 0 |
U.S. government debt securities | Significant Other Observable Inputs (Level 2) | ||
Assets | ||
Fair value of financial assets measured at fair value on a recurring basis | 67,301 | 119,340 |
U.S. government debt securities | Significant Unobservable Inputs (Level 3) | ||
Assets | ||
Fair value of financial assets measured at fair value on a recurring basis | 0 | 0 |
Equity securities | ||
Assets | ||
Fair value of financial assets measured at fair value on a recurring basis | 21,503 | 2,182 |
Equity securities | Quoted Prices in Active Markets (Level 1) | ||
Assets | ||
Fair value of financial assets measured at fair value on a recurring basis | 1,196 | 1,626 |
Equity securities | Significant Other Observable Inputs (Level 2) | ||
Assets | ||
Fair value of financial assets measured at fair value on a recurring basis | 266 | 556 |
Equity securities | Significant Unobservable Inputs (Level 3) | ||
Assets | ||
Fair value of financial assets measured at fair value on a recurring basis | 20,041 | 0 |
Other | ||
Assets | ||
Fair value of financial assets measured at fair value on a recurring basis | 715 | 659 |
Other | Quoted Prices in Active Markets (Level 1) | ||
Assets | ||
Fair value of financial assets measured at fair value on a recurring basis | 0 | 0 |
Other | Significant Other Observable Inputs (Level 2) | ||
Assets | ||
Fair value of financial assets measured at fair value on a recurring basis | 468 | 468 |
Other | Significant Unobservable Inputs (Level 3) | ||
Assets | ||
Fair value of financial assets measured at fair value on a recurring basis | $ 247 | $ 191 |
Fair Value Measurements - Sched
Fair Value Measurements - Schedule of Changes in Level 3 Investments (Details) - USD ($) $ in Thousands | 6 Months Ended | |
Jun. 30, 2019 | Jun. 30, 2018 | |
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] | ||
Dividend income from investments in preferred stock | $ 25 | $ 9,914 |
Significant Unobservable Inputs (Level 3) | ||
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] | ||
Beginning balance | 191 | |
Retained interest in deconsolidated subsidiary | 14,239 | |
Dividend income from investments in preferred stock | 25 | |
Net unrealized appreciation in the fair value of the investments in equity securities and preferred stock | 5,833 | |
Ending balance | $ 20,288 |
Fair Value Measurements - Addit
Fair Value Measurements - Additional Information (Details) - USD ($) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2019 | Jun. 30, 2019 | Dec. 31, 2018 | Jul. 31, 2018 | |
Significant Unobservable Inputs (Level 3) | ||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||
Fair value of financial liabilities measured at fair value on a recurring basis | $ 585,000 | $ 585,000 | $ 585,000 | |
Changes in fair value of Level 3 liabilities | $ 0 | $ 0 | ||
3.5% Convertible Notes Due 2023 | ||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||
Debt instrument, interest rate, stated percentage | 3.50% | 3.50% | 3.50% | |
Fair value of convertible debt | $ 112,000,000 | $ 112,000,000 | 141,000,000 | |
Carrying value of convertible debt | $ 152,634,000 | $ 152,634,000 | $ 148,101,000 | $ 143,723,000 |
Inventory (Details)
Inventory (Details) - USD ($) $ in Thousands | Jun. 30, 2019 | Dec. 31, 2018 |
Inventory [Line Items] | ||
Inventory | $ 18,192 | $ 21,447 |
Supplies, embryos and other production materials | ||
Inventory [Line Items] | ||
Inventory | 2,962 | 4,729 |
Work in process | ||
Inventory [Line Items] | ||
Inventory | 4,893 | 4,391 |
Livestock | ||
Inventory [Line Items] | ||
Inventory | 9,462 | 10,167 |
Feed | ||
Inventory [Line Items] | ||
Inventory | $ 875 | $ 2,160 |
Property, Plant and Equipment_3
Property, Plant and Equipment, Net - Schedule of Property, Plant and Equipment (Details) - USD ($) $ in Thousands | Jun. 30, 2019 | Dec. 31, 2018 |
Property, Plant and Equipment [Abstract] | ||
Land and land improvements | $ 11,674 | $ 12,490 |
Buildings and building improvements | 11,590 | 20,371 |
Furniture and fixtures | 1,684 | 1,891 |
Equipment | 68,138 | 74,555 |
Leasehold improvements | 31,925 | 28,289 |
Breeding stock | 4,675 | 4,582 |
Computer hardware and software | 12,131 | 11,697 |
Trees | 16,141 | 11,910 |
Construction and other assets in progress | 23,000 | 18,880 |
Property, plant and equipment, gross | 180,958 | 184,665 |
Less: Accumulated depreciation and amortization | (60,557) | (55,791) |
Property, plant and equipment, net | $ 120,401 | $ 128,874 |
Property, Plant and Equipment_4
Property, Plant and Equipment, Net - Additional Information (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2019 | Jun. 30, 2018 | Jun. 30, 2019 | Jun. 30, 2018 | |
Property, Plant and Equipment [Abstract] | ||||
Property, plant and equipment divested from deconsolidation | $ 24,186 | $ 24,186 | ||
Loss on disposal | $ 4,972 | $ 4,972 | ||
Depreciation expense | $ 3,347 | $ 3,642 | $ 6,920 | $ 7,098 |
Goodwill and Intangible Asset_3
Goodwill and Intangible Assets, Net - Schedule of Changes in Carrying Amount of Goodwill (Details) $ in Thousands | 6 Months Ended |
Jun. 30, 2019USD ($) | |
Goodwill | |
Beginning balance | $ 149,585 |
Foreign currency translation adjustments | 331 |
Ending balance | $ 149,916 |
Goodwill and Intangible Asset_4
Goodwill and Intangible Assets, Net - Additional Information (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | |||
Jun. 30, 2019 | Jun. 30, 2018 | Jun. 30, 2019 | Jun. 30, 2018 | Dec. 31, 2018 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |||||
Goodwill accumulated impairment losses | $ 13,823 | $ 13,823 | $ 13,823 | ||
Intangible assets divested from deconsolidation | 11,567 | 11,567 | |||
Amortization expense | $ 2,766 | $ 4,857 | $ 5,770 | $ 9,783 |
Goodwill and Intangible Asset_5
Goodwill and Intangible Assets, Net - Schedule of Intangible Assets (Details) - USD ($) $ in Thousands | Jun. 30, 2019 | Dec. 31, 2018 |
Finite-Lived Intangible Assets, Net [Abstract] | ||
Accumulated Amortization | $ (48,767) | $ (46,039) |
Intangible Assets | ||
Gross Carrying Amount | 161,293 | 175,330 |
Net | 112,526 | 129,291 |
Patents, developed technologies and know-how | ||
Finite-Lived Intangible Assets, Net [Abstract] | ||
Gross Carrying Amount | 139,363 | 152,482 |
Accumulated Amortization | (37,251) | (35,133) |
Net | 102,112 | 117,349 |
Customer relationships | ||
Finite-Lived Intangible Assets, Net [Abstract] | ||
Gross Carrying Amount | 10,700 | 10,700 |
Accumulated Amortization | (8,002) | (7,565) |
Net | 2,698 | 3,135 |
Trademarks | ||
Finite-Lived Intangible Assets, Net [Abstract] | ||
Gross Carrying Amount | 5,900 | 6,800 |
Accumulated Amortization | (3,514) | (3,341) |
Net | 2,386 | 3,459 |
In-process research and development | ||
Finite-Lived Intangible Assets, Net [Abstract] | ||
In-process research and development | $ 5,330 | $ 5,348 |
Lines of Credit and Long-Term_3
Lines of Credit and Long-Term Debt - Lines of Credit - Additional Information (Details) - Revolving Line of Credit | 6 Months Ended |
Jun. 30, 2019USD ($) | |
Trans Ova Genetics, LC | First National Bank of Omaha | |
Line of Credit Facility [Line Items] | |
Line of credit facility, maximum borrowing capacity | $ 8,000,000 |
Line of credit facility, interest rate at period end | 5.37% |
Line of credit facility, outstanding balance | $ 0 |
Trans Ova Genetics, LC | First National Bank of Omaha | Minimum | |
Line of Credit Facility [Line Items] | |
Debt instrument, interest rate, stated percentage | 3.00% |
Trans Ova Genetics, LC | First National Bank of Omaha | London Interbank Offered Rate (LIBOR) | |
Line of Credit Facility [Line Items] | |
Line of credit facility, basis spread on variable rate | 2.95% |
Exemplar Genetics, LLC | American State Bank | |
Line of Credit Facility [Line Items] | |
Line of credit facility, maximum borrowing capacity | $ 700,000 |
Debt instrument, interest rate, stated percentage | 5.75% |
Line of credit facility, outstanding balance | $ 387,000 |
Lines of Credit and Long-Term_4
Lines of Credit and Long-Term Debt - Schedule of Long-Term Debt Instruments (Details) - USD ($) $ in Thousands | Jun. 30, 2019 | Dec. 31, 2018 |
Debt Instrument [Line Items] | ||
Long-term debt | $ 212,947 | $ 211,794 |
Less current portion | 468 | 559 |
Long-term debt, less current portion | 212,479 | 211,235 |
Convertible debt | ||
Debt Instrument [Line Items] | ||
Long-term debt | 208,376 | 203,391 |
Notes payable | ||
Debt Instrument [Line Items] | ||
Long-term debt | 4,320 | 4,551 |
Other | ||
Debt Instrument [Line Items] | ||
Long-term debt | $ 251 | $ 3,852 |
Lines of Credit and Long-Term_5
Lines of Credit and Long-Term Debt - Long-Term Debt - Additional Information (Details) | 1 Months Ended | 3 Months Ended | 6 Months Ended | ||||
Dec. 31, 2018USD ($) | Sep. 30, 2018USD ($) | Jul. 31, 2018USD ($)day$ / shares | Jun. 30, 2019USD ($) | Jun. 30, 2018USD ($) | Jun. 30, 2019USD ($) | Jun. 30, 2018USD ($) | |
Debt Instrument [Line Items] | |||||||
Long-term debt divested from deconsolidation | $ 4,030,000 | $ 4,030,000 | |||||
Proceeds from long-term debt, net of issuance costs | 376,000 | $ 0 | |||||
Deferred income taxes | 473,000 | $ 1,015,000 | 981,000 | 5,089,000 | |||
Interest expense | 4,358,000 | $ 142,000 | 8,669,000 | $ 241,000 | |||
Long-term debt | $ 211,794,000 | 212,947,000 | 212,947,000 | ||||
Convertible debt | |||||||
Debt Instrument [Line Items] | |||||||
Long-term debt | 203,391,000 | 208,376,000 | 208,376,000 | ||||
Notes payable | |||||||
Debt Instrument [Line Items] | |||||||
Long-term debt | 4,551,000 | 4,320,000 | 4,320,000 | ||||
ActoBio Therapeutics Inc. | Convertible debt | Harvest Intrexon Enterprise Fund I, LP | |||||||
Debt Instrument [Line Items] | |||||||
Debt instrument, interest rate, stated percentage | 3.00% | ||||||
Interest expense | 228,000 | 453,000 | |||||
Long-term debt | $ 30,743,000 | $ 30,743,000 | |||||
Trans Ova Genetics, LC | Notes payable | American State Bank | |||||||
Debt Instrument [Line Items] | |||||||
Debt instrument, interest rate, stated percentage | 3.95% | 3.95% | |||||
Long-term debt | $ 4,281,000 | $ 4,281,000 | |||||
Debt instrument, periodic payment | 39,000 | ||||||
Harvest Intrexon Enterprise Fund I, LP | ActoBio Therapeutics Inc. | |||||||
Debt Instrument [Line Items] | |||||||
Long-term debt issued to a related party in an asset acquisition | $ 30,000,000 | ||||||
3.5% Convertible Notes Due 2023 | |||||||
Debt Instrument [Line Items] | |||||||
Aggregate principal amount | $ 200,000,000 | $ 200,000,000 | $ 200,000,000 | ||||
Proceeds from long-term debt, net of issuance costs | 193,958,000 | ||||||
Debt issuance costs | $ 6,042,000 | ||||||
Debt instrument, interest rate, stated percentage | 3.50% | 3.50% | 3.50% | ||||
Conversion rate | 58.6622 | ||||||
Principal amount used in conversion | $ 1,000 | ||||||
Conversion price (in usd per share) | $ / shares | $ 17.05 | ||||||
Debt instrument redemption price, percentage | 100.00% | ||||||
Carrying value of convertible debt | 148,101,000 | $ 143,723,000 | $ 152,634,000 | $ 152,634,000 | |||
Equity component of convertible debt, net of issuance costs and deferred taxes | 50,235,000 | ||||||
Deferred income taxes | $ 13,367,000 | ||||||
Effective interest rate on convertible notes | 11.02% | 11.02% | |||||
Convertible notes, unamortized discount and issuance costs | $ 47,366,000 | $ 47,366,000 | |||||
Total interest expense | 4,069,000 | 8,032,000 | |||||
Interest expense payable in cash | 1,750,000 | 3,500,000 | |||||
Noncash interest expense | $ 2,319,000 | $ 4,532,000 | |||||
3.5% Convertible Notes Due 2023 | Minimum | |||||||
Debt Instrument [Line Items] | |||||||
Common stock price trading days | day | 20 | ||||||
Common stock price consecutive trading days | day | 30 | ||||||
Percentage of common share price over conversion price for conversion | 130.00% | ||||||
3.5% Convertible Notes Due 2023 | Maximum | |||||||
Debt Instrument [Line Items] | |||||||
Common stock price trading days | day | 5 | ||||||
Common stock price consecutive trading days | day | 5 | ||||||
Debt instrument redemption price, percentage | 98.00% | ||||||
Merck Convertible Note | |||||||
Debt Instrument [Line Items] | |||||||
Aggregate principal amount | $ 25,000,000 | ||||||
Conversion rate upon IPO | 0.90 | ||||||
Interest rate applicable to IPO conversion event | 0.05 |
Lines of Credit and Long-Term_6
Lines of Credit and Long-Term Debt - Schedule of Future Maturities of Long-Term Debt (Details) $ in Thousands | Jun. 30, 2019USD ($) |
Debt Disclosure [Abstract] | |
2019 | $ 241 |
2020 | 31,254 |
2021 | 25,329 |
2022 | 339 |
2023 | 200,353 |
2024 | 366 |
Thereafter | 2,431 |
Total | $ 260,313 |
Income Taxes (Details)
Income Taxes (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2019 | Jun. 30, 2018 | Jun. 30, 2019 | Jun. 30, 2018 | |
Operating Loss Carryforwards [Line Items] | ||||
Deferred income tax benefit | $ 473 | $ 1,015 | $ 981 | $ 5,089 |
Deferred tax liabilities | 6,332 | 6,332 | ||
Domestic Tax Authority | ||||
Operating Loss Carryforwards [Line Items] | ||||
Taxable loss | 55,700 | 30,200 | 147,300 | 65,300 |
Current income tax expense (benefit) | 0 | 113 | ||
Operating and capital loss carryforwards | 516,400 | 516,400 | ||
Research and development tax credits | 8,800 | 8,800 | ||
Foreign Tax Authority | ||||
Operating Loss Carryforwards [Line Items] | ||||
Current income tax expense (benefit) | (52) | $ (112) | (122) | $ (237) |
Operating loss carryforwards | 162,900 | 162,900 | ||
Generated After 2017 | ||||
Operating Loss Carryforwards [Line Items] | ||||
Operating and capital loss carryforwards | $ 263,900 | $ 263,900 |
Shareholders' Equity - Issuance
Shareholders' Equity - Issuances of Intrexon Common Stock (Details) $ in Thousands | 1 Months Ended |
Jan. 31, 2018USD ($)shares | |
Class of Stock [Line Items] | |
Shares issued (in shares) | shares | 6,900,000 |
Net proceeds from public financing | $ 82,374 |
Underwriting discounts and commissions | 3,688 |
Capitalized offering expenses | $ 188 |
Affiliate of Third Security, LLC | |
Class of Stock [Line Items] | |
Shares issued (in shares) | shares | 1,000,000 |
Shareholders' Equity - Share Le
Shareholders' Equity - Share Lending Agreement (Details) | 1 Months Ended |
Jul. 31, 2018$ / sharesshares | |
Equity [Abstract] | |
Borrowed shares, number issued (in shares) | shares | 7,479,431 |
Borrowed shares, public offering price per share (in usd per share) | $ / shares | $ 13.37 |
Shareholders' Equity - Issuan_2
Shareholders' Equity - Issuances of AquaBounty Common Stock (Details) - USD ($) $ in Thousands | 1 Months Ended | 3 Months Ended | 6 Months Ended | ||||
Mar. 31, 2019 | Oct. 31, 2018 | Jan. 31, 2018 | Jun. 30, 2019 | Jun. 30, 2018 | Jun. 30, 2019 | Jun. 30, 2018 | |
Class of Stock [Line Items] | |||||||
Shares and warrants issued in public offerings, net of issuance costs | $ 6,611 | $ 87,990 | |||||
Net proceeds from exercises of warrants | $ 0 | $ 609 | $ 307 | $ 933 | |||
AquaBounty Technologies, Inc. | |||||||
Class of Stock [Line Items] | |||||||
Shares and warrants issued in public offerings, net of issuance costs | $ 6,611 | $ 10,616 | |||||
Net proceeds from exercises of warrants | $ 4,316 | ||||||
AquaBounty Technologies, Inc. | |||||||
Class of Stock [Line Items] | |||||||
Consolidation, less than wholly owned subsidiary, parent ownership interest, changes, purchase of interest by parent | $ 3,077 | $ 5,000 |
Shareholders' Equity - Componen
Shareholders' Equity - Components of Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Thousands | Jun. 30, 2019 | Dec. 31, 2018 |
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||
Intrexon shareholders' equity | $ 279,223 | $ 362,855 |
Unrealized gain (loss) on investments | ||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||
Intrexon shareholders' equity | 45 | (61) |
Loss on foreign currency translation adjustments | ||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||
Intrexon shareholders' equity | (28,251) | (28,551) |
Total accumulated other comprehensive loss | ||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||
Intrexon shareholders' equity | $ (28,206) | $ (28,612) |
Share-Based Payments - Schedule
Share-Based Payments - Schedule of Stock-Based Compensation Costs (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2019 | Jun. 30, 2018 | Jun. 30, 2019 | Jun. 30, 2018 | |
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||||
Stock-based compensation costs | $ 61 | $ 8,846 | $ 9,115 | $ 20,208 |
Cost of products | ||||
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||||
Stock-based compensation costs | 4 | 25 | 12 | 50 |
Cost of services | ||||
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||||
Stock-based compensation costs | 52 | 79 | 117 | 156 |
Research and development | ||||
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||||
Stock-based compensation costs | 1,882 | 2,376 | 3,727 | 5,634 |
Selling, general and administrative | ||||
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||||
Stock-based compensation costs | $ (1,877) | $ 6,366 | $ 5,259 | $ 14,368 |
Share-Based Payments - Addition
Share-Based Payments - Additional Information (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | |||
Jun. 30, 2019 | Jun. 30, 2018 | Jun. 30, 2019 | Jun. 30, 2018 | Aug. 31, 2013 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Shares issued as payment for services | $ 5,688 | $ 5,487 | |||
Chief Executive Officer | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Monthly compensation, in the form of equity | $ 200 | ||||
Lock-up period | 3 years | ||||
Chief Executive Officer | Selling, general and administrative | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Shares issued as payment for services | $ 495 | $ 483 | $ 981 | $ 969 | |
Intrexon Stock Option Plan - 2008 Plan | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Remaining shares available to grant (in shares) | 0 | ||||
Options outstanding (in shares) | 393,098 | 393,098 | |||
Intrexon Stock Option Plan - 2013 Plan | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Remaining shares available to grant (in shares) | 6,397,402 | 6,397,402 | |||
Options outstanding (in shares) | 11,337,856 | 11,337,856 | |||
Number of shares authorized for issuance (in shares) | 25,000,000 | 25,000,000 | |||
RSUs outstanding (in shares) | 2,271,277 | 2,271,277 | |||
Intrexon Stock Option Plan - 2019 Plan | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Remaining shares available to grant (in shares) | 4,853,513 | 4,853,513 | |||
Number of shares authorized for issuance (in shares) | 5,000,000 | 5,000,000 |
Share-Based Payments - Schedu_2
Share-Based Payments - Schedule of Stock Option Activity (Details) - Intrexon Stock Option Plans - $ / shares | 6 Months Ended | 12 Months Ended |
Jun. 30, 2019 | Dec. 31, 2018 | |
Number of Shares | ||
Balances at beginning of period (in shares) | 11,093,063 | |
Granted (in shares) | 1,433,075 | |
Exercised (in shares) | (17,811) | |
Forfeited (in shares) | (634,204) | |
Expired (in shares) | (143,169) | |
Balances at end of period (in shares) | 11,730,954 | 11,093,063 |
Exercisable at end of period (in shares) | 8,179,447 | |
Weighted Average Exercise Price | ||
Balances at beginning of period (in usd per share) | $ 27.95 | |
Granted (in usd per share) | 6.46 | |
Exercised (in usd per share) | (3.17) | |
Forfeited (in usd per share) | (35.36) | |
Expired (in usd per share) | (28.38) | |
Balances at period end (in usd per share) | 24.96 | $ 27.95 |
Exercisable, weighted average exercise price, at end of period (in usd per share) | $ 28.82 | |
Weighted Average Remaining Contractual Term (Years) | ||
Balances, weighted average remaining contractual period | 5 years 9 months | 6 years 9 months 21 days |
Exercisable at period end, weighted average remaining contractual period | 4 years 6 months 7 days |
Share-Based Payments - Schedu_3
Share-Based Payments - Schedule of Restricted Stock Unit Activity (Details) - $ / shares | 6 Months Ended | 12 Months Ended |
Jun. 30, 2019 | Dec. 31, 2018 | |
Number of Restricted Stock Units | ||
Forfeited (in shares) | (212,412) | |
Weighted Average Grant Date Fair Value | ||
Forfeited (in usd per share) | $ (9.20) | |
Intrexon Stock Option Plans | ||
Number of Restricted Stock Units | ||
Balances at beginning of period (in shares) | 970,341 | |
Granted (in shares) | 2,278,460 | |
Vested (in shares) | (765,112) | |
Balances at end of period (in shares) | 2,271,277 | 970,341 |
Weighted Average Grant Date Fair Value | ||
Balances at beginning of period (in usd per share) | $ 13.82 | |
Granted (in usd per share) | 6.59 | |
Vested (in usd per share) | (9.75) | |
Balances at end of period (in usd per share) | $ 8.37 | $ 13.82 |
Additional Information | ||
Weighted Average Remaining Contractual Term (Years) | 1 year 5 months 26 days | 1 year 5 months 4 days |
Operating Leases - Additional I
Operating Leases - Additional Information (Details) $ in Thousands | 6 Months Ended |
Jun. 30, 2019USD ($) | |
Lessee, Lease, Description [Line Items] | |
Termination period | 1 year |
Operating lease commitment not yet commenced | $ 1,400 |
Operating leases not yet commenced, term of contract | 3 years |
Minimum | |
Lessee, Lease, Description [Line Items] | |
Term of contract | 1 year |
Maximum | |
Lessee, Lease, Description [Line Items] | |
Term of contract | 20 years |
Operating Leases - Components o
Operating Leases - Components of Lease Costs (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended |
Jun. 30, 2019 | Jun. 30, 2019 | |
Leases [Abstract] | ||
Operating lease costs | $ 2,522 | $ 5,048 |
Short-term and variable lease costs | 1,120 | 2,168 |
Lease costs | $ 3,642 | $ 7,216 |
Operating Leases - Maturities o
Operating Leases - Maturities of Lease Liabilities (Details) - USD ($) $ in Thousands | Jun. 30, 2019 | Dec. 31, 2018 |
Lessee, Operating Lease, Liability, Payment, Due [Abstract] | ||
2019 | $ 4,352 | |
2020 | 10,088 | |
2021 | 9,445 | |
2022 | 8,646 | |
2023 | 7,274 | |
2024 | 7,139 | |
Thereafter | 26,746 | |
Total | 73,690 | |
Present value adjustment | (30,120) | |
Total | 43,570 | |
Current portion of lease liabilities | 4,813 | $ 0 |
Long-term portion of operating lease liabilities | $ 38,757 | $ 0 |
Operating Leases - Other Inform
Operating Leases - Other Information (Details) $ in Thousands | 6 Months Ended |
Jun. 30, 2019USD ($) | |
Supplemental Cash Flows Information | |
Cash paid for operating lease liabilities | $ 4,929 |
Operating lease right-of-use assets added in exchange for new lease liabilities | $ 1,125 |
Operating Leases - Lease Terms
Operating Leases - Lease Terms and Discount Rates (Details) | Jun. 30, 2019 |
Leases [Abstract] | |
Weighted average remaining lease term (years) | 8 years 11 months 23 days |
Weighted average discount rate | 11.35% |
Operating Leases - Future Minim
Operating Leases - Future Minimum Lease Payments (Details) $ in Thousands | Dec. 31, 2018USD ($) |
Contractual Obligation, Fiscal Year Maturity Schedule [Abstract] | |
2019 | $ 9,182 |
2020 | 9,910 |
2021 | 9,127 |
2022 | 8,305 |
2023 | 7,229 |
Thereafter | 34,157 |
Total | $ 77,910 |
Commitments and Contingencies -
Commitments and Contingencies - Purchase Commitments - Additional Information (Details) $ in Thousands | Jun. 30, 2019USD ($) |
Commitments and Contingencies Disclosure [Abstract] | |
Outstanding contractual purchase commitments | $ 10,384 |
Commitments and Contingencies_2
Commitments and Contingencies - Contingencies - Additional Information (Details) - Licensing and patent infringement suit | 1 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended | 38 Months Ended | 50 Months Ended | |
Mar. 31, 2019 | Apr. 30, 2016USD ($) | Jun. 30, 2019USD ($)claim | Jun. 30, 2019USD ($)claim | Dec. 31, 2016USD ($) | Mar. 31, 2019USD ($) | Apr. 30, 2016USD ($) | |
Loss Contingencies [Line Items] | |||||||
Damages awarded to Trans Ova | $ 528,000 | ||||||
Back royalties | $ 1,000,000 | ||||||
Litigation settlement, aggregate royalty and license payment | $ 5,801,000 | $ 3,170,000 | |||||
Royalty payments not yet deposited | 2,759,000 | $ 2,759,000 | |||||
Litigation settlement expense | $ 4,228,000 | ||||||
Royalty expense | $ 267,000 | $ 383,000 | |||||
XY, LLC | |||||||
Loss Contingencies [Line Items] | |||||||
Damages awarded against Trans Ova | $ 6,066,000 | ||||||
Litigation settlement, ongoing royalty percentage | 12.50% | 18.75% | |||||
Enhancement rate on products utilizing reverse sorting | 2.00% | ||||||
Cumulative payments for royalties and licenses | $ 5 | $ 6.25 | |||||
Weighted blended royalty rate | 12.63% | ||||||
Claims dismissed (in claims) | claim | 9 | ||||||
Total claims | claim | 12 | ||||||
Claims pending resolution | claim | 2 | 2 |
Related Party Transactions - A
Related Party Transactions - Additional Information (Details) - USD ($) | 1 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||||
Nov. 30, 2017 | Mar. 31, 2017 | Jun. 30, 2016 | Nov. 30, 2015 | Jun. 30, 2019 | Jun. 30, 2018 | Jun. 30, 2019 | Jun. 30, 2018 | Dec. 31, 2018 | |
Related Party Transaction [Line Items] | |||||||||
Shares issued as payment for services | $ 4,857,000 | $ 2,546,000 | $ 5,688,000 | $ 5,487,000 | |||||
Noncash dividend income | 25,000 | 9,914,000 | |||||||
Fair value of financial assets measured at fair value on a recurring basis | 89,519,000 | 89,519,000 | $ 122,181,000 | ||||||
Revenues | 35,986,000 | 45,275,000 | 59,321,000 | 84,941,000 | |||||
Third Security, LLC | |||||||||
Related Party Transaction [Line Items] | |||||||||
Initial term of services agreement | 1 year | ||||||||
Expense for services | $ 1,000 | $ 3,000 | $ 18,000 | $ 17,000 | |||||
Shares issued as payment for services (in shares) | 483,279 | 139,691 | 839,993 | 300,317 | |||||
Shares issued as payment for services | $ 2,284,000 | $ 2,064,000 | $ 4,362,000 | $ 4,105,000 | |||||
Sublease rental income | 22,000 | $ 23,000 | 44,000 | 44,000 | |||||
Third Security, LLC | Common Stock | |||||||||
Related Party Transaction [Line Items] | |||||||||
Expense for services | $ 800,000 | ||||||||
Histogenics Corporation, OvaScience Inc., and Synthetic Biologics Inc. | |||||||||
Related Party Transaction [Line Items] | |||||||||
Revenues | $ 3,183,000 | 11,877,000 | |||||||
Convertible Note and Warrants | Other Noncurrent Assets | Fibrocell Science, Inc. | |||||||||
Related Party Transaction [Line Items] | |||||||||
Fair value of financial assets measured at fair value on a recurring basis | $ 128,000 | $ 128,000 | 120,000 | ||||||
Third Security, LLC | Chief Executive Officer | |||||||||
Related Party Transaction [Line Items] | |||||||||
Ownership interest | 100.00% | 100.00% | |||||||
ZIOPHARM Oncology, Inc. | |||||||||
Related Party Transaction [Line Items] | |||||||||
Preferred shares, stated value (in usd per share) | $ 1,200 | ||||||||
Preferred shares, dividend rate (in usd per share) | $ 12 | ||||||||
Fibrocell Science, Inc. | |||||||||
Related Party Transaction [Line Items] | |||||||||
Convertible preferred shares issued (in shares) | 1,161 | ||||||||
Warrants, number of common shares into which warrants can be converted (in shares) | 99,769 | ||||||||
Convertible preferred shares, dividend rate | 4.00% | ||||||||
ZIOPHARM Oncology, Inc. | |||||||||
Related Party Transaction [Line Items] | |||||||||
Dividend income, number of preferred shares received (in shares) | 3,734 | 7,358 | |||||||
Noncash dividend income | $ 5,019,000 | $ 9,890,000 | |||||||
Fibrocell Science, Inc. | |||||||||
Related Party Transaction [Line Items] | |||||||||
Purchases of preferred stock and warrants | $ 1,161,000 | ||||||||
Preferred stock | Fibrocell Science, Inc. | Other Noncurrent Assets | |||||||||
Related Party Transaction [Line Items] | |||||||||
Fair value of financial assets measured at fair value on a recurring basis | $ 247,000 | $ 247,000 | 191,000 | ||||||
Preferred stock | Oragenics, Inc. | |||||||||
Related Party Transaction [Line Items] | |||||||||
Fair value of financial assets measured at fair value on a recurring basis | $ 0 | $ 0 | $ 0 | ||||||
Receivables converted to preferred stock | $ 3,385,000 | ||||||||
Preferred shares, initial dividend rate | 12.00% | ||||||||
Preferred shares, subsequent dividend rate | 20.00% | ||||||||
ZIOPHARM Oncology, Inc. | |||||||||
Related Party Transaction [Line Items] | |||||||||
Collaborative arrangement consideration received, number of preferred shares (in shares) | 100,000 |
Net Loss per Share - Computatio
Net Loss per Share - Computation of Basic and Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2019 | Jun. 30, 2018 | Jun. 30, 2019 | Jun. 30, 2018 | |
Numerator: | ||||
Net loss attributable to Intrexon | $ (38,766) | $ (65,382) | $ (99,475) | $ (111,547) |
Denominator: | ||||
Weighted average shares outstanding, basic and diluted (in shares) | 153,749,929 | 129,299,584 | 153,351,208 | 128,500,897 |
Net loss attributable to Intrexon per share, basic and diluted (in usd per share) | $ (0.25) | $ (0.51) | $ (0.65) | $ (0.87) |
Net Loss per Share - Schedule o
Net Loss per Share - Schedule of Antidilutive Securities Excluded from Calculation of Net Loss per Share (Details) - shares | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2019 | Jun. 30, 2018 | Jun. 30, 2019 | Jun. 30, 2018 | |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||||
Antidilutive securities excluded from computation of net loss per share (in shares) | 33,803,260 | 12,525,879 | 33,803,260 | 12,525,879 |
Convertible debt | ||||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||||
Antidilutive securities excluded from computation of net loss per share (in shares) | 19,667,765 | 0 | 19,667,765 | 0 |
Options | ||||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||||
Antidilutive securities excluded from computation of net loss per share (in shares) | 11,730,954 | 11,359,531 | 11,730,954 | 11,359,531 |
Restricted stock units | ||||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||||
Antidilutive securities excluded from computation of net loss per share (in shares) | 2,271,277 | 1,033,084 | 2,271,277 | 1,033,084 |
Warrants | ||||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||||
Antidilutive securities excluded from computation of net loss per share (in shares) | 133,264 | 133,264 | 133,264 | 133,264 |
Segments - Information by Repor
Segments - Information by Reportable Segment (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2019 | Jun. 30, 2018 | Jun. 30, 2019 | Jun. 30, 2018 | |
Segment Reporting Information [Line Items] | ||||
Revenues from external customers | $ 35,986 | $ 45,275 | $ 59,321 | $ 84,941 |
Segment Adjusted EBITDA | (32,940) | (28,948) | (66,219) | (58,348) |
Precigen | ||||
Segment Reporting Information [Line Items] | ||||
Segment Adjusted EBITDA | (7,467) | (7,858) | (14,836) | (12,832) |
Methane Bioconversion Platform | ||||
Segment Reporting Information [Line Items] | ||||
Segment Adjusted EBITDA | (9,188) | (7,629) | (17,214) | (13,867) |
Fine Chemicals | ||||
Segment Reporting Information [Line Items] | ||||
Segment Adjusted EBITDA | 855 | 901 | 1,742 | 1,893 |
Okanagan | ||||
Segment Reporting Information [Line Items] | ||||
Segment Adjusted EBITDA | (12,012) | (6,280) | (21,123) | (11,451) |
Trans Ova | ||||
Segment Reporting Information [Line Items] | ||||
Segment Adjusted EBITDA | 4,932 | 2,096 | 2,706 | (57) |
All Other | ||||
Segment Reporting Information [Line Items] | ||||
Segment Adjusted EBITDA | (10,060) | (10,178) | (17,494) | (22,034) |
Operating segments | ||||
Segment Reporting Information [Line Items] | ||||
Revenues from external customers | 35,947 | 45,285 | 59,174 | 84,996 |
Revenues | 40,518 | 47,036 | 68,333 | 88,839 |
Operating segments | Precigen | ||||
Segment Reporting Information [Line Items] | ||||
Revenues from external customers | 549 | 7,332 | 1,730 | 15,463 |
Revenues | 2,961 | 7,442 | 6,507 | 15,694 |
Operating segments | Methane Bioconversion Platform | ||||
Segment Reporting Information [Line Items] | ||||
Revenues from external customers | 1,215 | 1,371 | 2,696 | 2,947 |
Revenues | 1,217 | 1,375 | 2,698 | 2,953 |
Operating segments | Fine Chemicals | ||||
Segment Reporting Information [Line Items] | ||||
Revenues from external customers | 1,180 | 1,426 | 1,990 | 3,108 |
Revenues | 2,551 | 2,721 | 4,855 | 5,902 |
Operating segments | Okanagan | ||||
Segment Reporting Information [Line Items] | ||||
Revenues from external customers | 19 | 20 | 39 | 27 |
Revenues | 19 | 20 | 39 | 27 |
Operating segments | Trans Ova | ||||
Segment Reporting Information [Line Items] | ||||
Revenues from external customers | 24,392 | 25,780 | 39,326 | 43,987 |
Revenues | 25,066 | 25,857 | 40,273 | 44,079 |
Operating segments | All Other | ||||
Segment Reporting Information [Line Items] | ||||
Revenues from external customers | 8,592 | 9,356 | 13,393 | 19,464 |
Revenues | 8,704 | 9,621 | 13,961 | 20,184 |
Intersegment revenues | ||||
Segment Reporting Information [Line Items] | ||||
Revenues | 4,571 | 1,751 | 9,159 | 3,843 |
Intersegment revenues | Precigen | ||||
Segment Reporting Information [Line Items] | ||||
Revenues | 2,412 | 110 | 4,777 | 231 |
Intersegment revenues | Methane Bioconversion Platform | ||||
Segment Reporting Information [Line Items] | ||||
Revenues | 2 | 4 | 2 | 6 |
Intersegment revenues | Fine Chemicals | ||||
Segment Reporting Information [Line Items] | ||||
Revenues | 1,371 | 1,295 | 2,865 | 2,794 |
Intersegment revenues | Okanagan | ||||
Segment Reporting Information [Line Items] | ||||
Revenues | 0 | 0 | 0 | 0 |
Intersegment revenues | Trans Ova | ||||
Segment Reporting Information [Line Items] | ||||
Revenues | 674 | 77 | 947 | 92 |
Intersegment revenues | All Other | ||||
Segment Reporting Information [Line Items] | ||||
Revenues | $ 112 | $ 265 | $ 568 | $ 720 |
Segments - Reconciliation of Re
Segments - Reconciliation of Revenues from Reportable Segments to Consolidated Revenues (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2019 | Jun. 30, 2018 | Jun. 30, 2019 | Jun. 30, 2018 | |
Segment Reporting, Asset Reconciling Item [Line Items] | ||||
Revenues | $ 35,986 | $ 45,275 | $ 59,321 | $ 84,941 |
Other revenues, including from other operating segments | ||||
Segment Reporting, Asset Reconciling Item [Line Items] | ||||
Revenues | 8,743 | 9,726 | 14,108 | 20,581 |
Elimination of intersegment revenues | ||||
Segment Reporting, Asset Reconciling Item [Line Items] | ||||
Revenues | (4,571) | (1,866) | (9,159) | (4,295) |
Total revenues from reportable segments | ||||
Segment Reporting, Asset Reconciling Item [Line Items] | ||||
Revenues | $ 31,814 | $ 37,415 | $ 54,372 | $ 68,655 |
Segments - Reconciliation of Ne
Segments - Reconciliation of Net Loss Before Income Taxes (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2019 | Jun. 30, 2018 | Jun. 30, 2019 | Jun. 30, 2018 | |
Segment Reporting Information [Line Items] | ||||
Segment Adjusted EBITDA | $ (32,940) | $ (28,948) | $ (66,219) | $ (58,348) |
Other expenses: | ||||
Interest expense | (4,358) | (142) | (8,669) | (241) |
Depreciation and amortization | (12,690) | (16,881) | ||
Stock-based compensation expense | (61) | (8,846) | (9,115) | (20,208) |
Equity in net loss of affiliates | (1,747) | (4,550) | (3,387) | (7,010) |
Loss before income taxes | (39,456) | (67,956) | (102,170) | (119,451) |
Operating segments | ||||
Segment Reporting Information [Line Items] | ||||
Remove cash paid for capital expenditures and investments in affiliates | 14,695 | 9,668 | 25,985 | 20,049 |
Corporate And Reconciling Items | ||||
Other expenses: | ||||
Interest expense | (4,358) | (142) | (8,669) | (241) |
Depreciation and amortization | (6,113) | (8,499) | (12,690) | (16,881) |
Stock-based compensation expense | (61) | (8,846) | (9,115) | (20,208) |
Equity in net loss of affiliates | (1,747) | (4,550) | (3,387) | (7,010) |
Unallocated corporate costs | ||||
Other expenses: | ||||
Loss before income taxes | (13,032) | (33,122) | (32,978) | (52,673) |
Eliminations | ||||
Other expenses: | ||||
Loss before income taxes | (3,162) | (571) | (6,012) | (1,038) |
Reportable segments | ||||
Segment Reporting Information [Line Items] | ||||
Segment Adjusted EBITDA | (22,880) | (18,770) | (48,725) | (36,314) |
All Other | ||||
Segment Reporting Information [Line Items] | ||||
Segment Adjusted EBITDA | (10,060) | (10,178) | (17,494) | (22,034) |
Upfront and Milestone Payments | Operating segments | ||||
Segment Reporting Information [Line Items] | ||||
Add recognition of previously deferred revenue associated with upfront and milestone payments | $ 7,262 | $ 7,054 | $ 10,915 | $ 16,899 |
Segments - Additional Informati
Segments - Additional Information (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | |||
Jun. 30, 2019 | Jun. 30, 2018 | Jun. 30, 2019 | Jun. 30, 2018 | Dec. 31, 2018 | |
Segment Reporting Information [Line Items] | |||||
Property, plant and equipment, net | $ 120,401 | $ 120,401 | $ 128,874 | ||
Non-US | |||||
Segment Reporting Information [Line Items] | |||||
Property, plant and equipment, net | 8,753 | 8,753 | $ 16,839 | ||
Revenues | $ 2,195 | $ 3,951 | $ 4,460 | $ 8,154 |
Subsequent Events (Details)
Subsequent Events (Details) - USD ($) $ in Thousands | 2 Months Ended | 3 Months Ended | 6 Months Ended | 17 Months Ended | ||
Jan. 31, 2021 | Sep. 30, 2019 | Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2018 | Dec. 31, 2020 | |
Subsequent Event [Line Items] | ||||||
Payments to acquire interest in entity | $ 37,163 | $ 76 | ||||
Subsequent Event | Forecast | Third Party Investor | Investment and Contribution Agreement | ||||||
Subsequent Event [Line Items] | ||||||
Payments to acquire interest in entity | $ 20,000 | $ 20,000 | $ 20,000 | $ 60,000 |